Basic Information

Professional Memberships

• 日本呼吸器学会
• 米国癌学会（AACR)
• 日本癌学会
• 日本肺癌学会

Academic Degree

• 博士（医学）(名古屋市立大学)

Research History

• From May 2002, To Feb. 2004

  名古屋市立大学病院, 第2内科, 研修医
• From Mar. 2004, To Mar. 2006

  岐阜県立多治見病院, 呼吸器内科, 医員
• From Apr. 2006, To Mar. 2011

  Nagoya City University Graduate School of Medical Sciences, Department of Medical Oncology and Immunology, Graduate School of Medical Sciences, 腫瘍・免疫内科学, Assistant Professor
• From Apr. 2011, To Oct. 2012

  名古屋市立大学大学院医学研究科, 腫瘍・免疫内科学, 助教
• From Nov. 2012, To Dec. 2012

  京都大学大学院医学研究科, 呼吸器内科学, 医員
• From Jan. 2013, To Mar. 2015

  京都大学大学院医学研究科, 集学的がん診療学講座, 特定病院助教
• From Apr. 2015, To Sep. 2021

  京都大学大学院医学研究科, 呼吸器内科学, 助教
• From Oct. 2021, To Present

  京都大学大学院医学研究科, 呼吸器内科学, 病院講師
• From Apr. 2023, To Present

  京都大学医学部附属病院, がん診療部, 肺癌診療ユニット長

Language of Instruction

• Japanese

ID,URL

• J-Global ID

  201101025890663213

researchmap URL

• https://researchmap.jp/HOZASA

Research

Research Areas

• Life sciences, Tumor diagnostics and therapeutics, 肺癌、治療初期生存、獲得耐性、転移性腫瘍、腫瘍微小環境、一塩基多型

Papers

• 新たな肺腺癌脳転移モデルを用いた抗PD-1/CTLA-4抗体併用療法の有効性と作用機序の検討(Novel Model of Lung Adenocarcinoma Brain Metastasis Reveals Efficacy of Anti-PD-1/CTLA-4 Combination Therapy)

  細谷 和貴; 小笹 裕晃; 辻 貴宏; 島 佑介; 住永 圭一郎; 橋本 健太郎; 吉田 寛; 味水 瞳; 船造 智子; 吉田 博徳; 野溝 岳; 和氣 弘明; 平井 豊博; 辻 貴宏

  日本癌学会総会記事, Sep. 2024

  
• 非小細胞肺癌におけるgemcitabine効果予測因子としてのhENT1発現検討(The absence of hENT1 expression predicts nonresponse to gemcitabine-containing chemotherapy in NSCLC)

  小栗 鉄也; 阿知和 宏行; 村松 秀樹; 小笹 裕晃; 上村 剛大; 宮崎 幹規; 前野 健; 清水 重喜; 前田 浩義; 佐藤 滋樹; 上田 龍三

  日本癌学会総会記事, Aug. 2007

  
• Phase II Study of Consolidation Amrubicin after Concurrent Chemoradiotherapy in Patients with Limited-stage Small-cell Lung Cancer

  Yoshida, H.; Nagai, H.; Sakamori, Y.; Ozasa, H.; Nishimura, T.; Tomii, K.; Hirai, T.; Matsuo, Y.; Iizuka, Y.; Mizowaki, T.; Yoshimura, K.; Kim, Y.H.

  In Vivo, 2020

  
• Safety and efficacy of pemetrexed for patients with non-small cell lung cancer in the setting of renal impairment: a retrospective study

  Yusuke Shima; Hironori Yoshida; Keiichiro Suminaga; Hiroshi Yoshida; Kentaro Hashimoto; Tatsuya Ogimoto; Kazutaka Hosoya; Hitomi Ajimizu; Tomoko Funazo; Takashi Nomizo; Hiroaki Ozasa; Toyohiro Hirai

  BMC Cancer, 04 Mar. 2025

  
• Usefulness of pro-gastrin-releasing peptide as a predictor of the incidence of brain metastasis and effect of prophylactic cranial irradiation in patients with limited-stage small-cell lung cancer

  Ueki, Kazuhito; Matsuo, Yukinori; Kishi, Noriko; Yoneyama, Masahiro; Yoshida, Hironori; Sakamori, Yuichi; Ozasa, Hiroaki; Hirai, Toyohiro; Mizowaki, Takashi

  Journal of Radiation Research, Jul. 2022

  Access this paper :

  
• The impact of PD-L1 polymorphisms on the efficacy of immune checkpoint inhibitors depends on the tumor proportion score: a retrospective study

  Keiichiro Suminaga; Takashi Nomizo; Hironori Yoshida; Hiroaki Ozasa

  Journal of Cancer Research and Clinical Oncology, 04 Feb. 2025

  Access this paper :

  
• Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

  Myung-Ju Ahn; Kentaro Tanaka; Luis Paz-Ares; Robin Cornelissen; Nicolas Girard; Elvire Pons-Tostivin; David Vicente Baz; Shunichi Sugawara; Manuel Cobo; Maurice Pérol; Céline Mascaux; Elena Poddubskaya; Satoru Kitazono; Hidetoshi Hayashi; Min Hee Hong; Enriqueta Feli; Richard Hall; Oscar Juan-Vidal; Daniel Brungs; Shun Lu; Marina Garassino; Michael Chargualaf; Yong Zhang; Paul Howarth; Deise Uema; Aaron Lisberg; Jacob Sands; TROPION-Lung Trial Investigators

  J Clin Oncol ., Sep. 2024, Peer-reviewed

  
• Characteristics and outcomes of salvage surgery after immune checkpoint inhibitor therapy for initially unresectable non-small cell lung cancer.

  Masatsugu Hamaji; Hiroaki Ozasa; Yuichi Sakamori; Kazuhiro Terada; Akihiko Yoshizawa; Ryutaro Kikuchi; Yasuto Sakaguchi; Makoto Sonobe; Yusuke Muranishi; Ryo Miyahara; Hideki Motoyama; Mitsugu Omasa; Hiroshi Date

  Journal of thoracic disease, 30 Sep. 2024, Peer-reviewed

  Access this paper :

  
• Trochlear nerve schwannoma with concomitant osimertinib-responsive stage IV lung adenocarcinoma: illustrative case.

  Shunya Kashiwagi; Masahiro Tanji; Toshiki Matsuoka; Noritaka Sano; Hiroaki Ozasa; Daisuke Natori; Yasuhide Takeuchi; Yasuhide Makino; Etsuko Yamamoto Hattori; Yukinori Terada; Yohei Mineharu; Yoshiki Arakawa

  Journal of neurosurgery. Case lessons, 12 Aug. 2024, Peer-reviewed

  Access this paper :

  
• Subjective symptoms are triggers for the detection of immune checkpoint inhibitor-induced interstitial lung disease and associate with disease severity: a single-center retrospective study.

  Mari Yokoi; Atsushi Yonezawa; Daiki Hira; Tomohiro Handa; Kiminobu Tanizawa; Shunsaku Nakagawa; Masahiro Tsuda; Yasuaki Ikemi; Ryo Itotani; Hironori Yoshida; Motoo Nomura; Junichi Matsubara; Kosaku Murakami; Hiroaki Ozasa; Manabu Muto; Tomohiro Terada

  Journal of pharmaceutical health care and sciences, 27 Aug. 2024, Peer-reviewed

  
• Performance status improvement and advances in systemic treatment after brain metastases resection: a retrospective single-center cohort study of non-small cell lung cancer patients.

  Kazutaka Hosoya; Hiroaki Ozasa; Masahiro Tanji; Hiroshi Yoshida; Hitomi Ajimizu; Takahiro Tsuji; Hironori Yoshida; Yukinori Terada; Noritaka Sano; Yohei Mineharu; Susumu Miyamoto; Toyohiro Hirai; Yoshiki Arakawa

  BMC cancer, 21 Aug. 2024, Peer-reviewed

  
• Quantitative analysis of interstitial lung abnormalities on computed tomography to predict symptomatic radiation pneumonitis after lung stereotactic body radiotherapy.

  Masahiro Yoneyama; Yukinori Matsuo; Noriko Kishi; Ryo Itotani; Tsuyoshi Oguma; Hiroaki Ozasa; Kiminobu Tanizawa; Tomohiro Handa; Toyohiro Hirai; Takashi Mizowaki

  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, Sep. 2024, Peer-reviewed

  
• Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade.

  Hidetoshi Hayashi; Kenji Chamoto; Ryusuke Hatae; Takashi Kurosaki; Yosuke Togashi; Kazuya Fukuoka; Megumi Goto; Yasutaka Chiba; Shuta Tomida; Takayo Ota; Koji Haratani; Takayuki Takahama; Junko Tanizaki; Takeshi Yoshida; Tsutomu Iwasa; Kaoru Tanaka; Masayuki Takeda; Tomoko Hirano; Hironori Yoshida; Hiroaki Ozasa; Yuichi Sakamori; Kazuko Sakai; Keiko Higuchi; Hitoshi Uga; Chihiro Suminaka; Toyohiro Hirai; Kazuto Nishio; Kazuhiko Nakagawa; Tasuku Honjo

  The Journal of clinical investigation, 01 Apr. 2024, Peer-reviewed

  
• Aurora kinase B inhibition in small-cell lung cancer: BCL-2 as a potential therapeutic biomarker and combination target.

  Kazutaka Hosoya; Hiroaki Ozasa

  Translational lung cancer research, 29 Mar. 2024, Peer-reviewed, Corresponding author

  
• Immune checkpoint inhibitors in patients with lung cancer having chronic interstitial pneumonia.

  Kazutoshi Isobe; Yasuhiko Nakamura; Susumu Sakamoto; Keisuke Tomii; Takayuki Takimoto; Yasunari Miyazaki; Masaru Matsumoto; Keishi Sugino; Kazuya Ichikado; Shuhei Moriguchi; Kakuhiro Yamaguchi; Tomohisa Baba; Hiroaki Ozasa; Fumiyasu Igata; Kazuki Anabuki; Sakae Homma; Hiroshi Date; Takafumi Suda; Kazuma Kishi

  ERJ open research, Mar. 2024, Peer-reviewed

  
• Successful treatment of lung cancer coexisting with B‑cell lymphoma with pembrolizumab following rituximab‑included chemotherapy: A case report.

  Daisuke Natori; Hiroaki Ozasa; Yusuke Shima; Chisaki Mizumoto; Keiichiro Suminaga; Takashi Nomizo; Hitomi Ajimizu; Hironori Yoshida; Toyohiro Hirai

  Molecular and clinical oncology, Apr. 2024, Peer-reviewed

  
• Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation-positive Lung Cancer.

  Tatsuya Ogimoto; Hiroaki Ozasa; Takahiro Tsuji; Tomoko Funazo; Masatoshi Yamazoe; Kentaro Hashimoto; Hiroshi Yoshida; Kazutaka Hosoya; Hitomi Ajimizu; Takashi Nomizo; Hironori Yoshida; Masatsugu Hamaji; Toshi Menju; Akihiko Yoshizawa; Hiroshi Date; Toyohiro Hirai

  Molecular cancer therapeutics, 02 Apr. 2024, Peer-reviewed, Corresponding author

  
• CD47 polymorphism for predicting nivolumab benefit in patients with advanced non‑small‑cell lung cancer.

  Tatsuya Ogimoto; Hiroaki Ozasa; Hironori Yoshida; Takashi Nomizo; Tomoko Funazo; Hiroshi Yoshida; Kentaro Hashimoto; Kazutaka Hosoya; Masatoshi Yamazoe; Hitomi Ajimizu; Takahiro Tsuji; Yuichi Sakamori; Kiyomitsu Kuninaga; Satoshi Morita; Toyohiro Hirai

  Oncology letters, Aug. 2023, Peer-reviewed, Corresponding author

  
• Phase II study of consolidation amrubicin after concurrent chemoradiotherapy for patients with limited-stage small cell lung cancer.

  Hironori Yoshida; Young Hak Kim; Hiroaki Ozasa; Yuichi Sakamori; Takashi Nishimura; Keisuke Tomii; Tadashi Mio; Toyohiro Hirai

  JOURNAL OF CLINICAL ONCOLOGY, May 2019

  
• Author Correction: Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer.

  Hitomi Ajimizu; Hiroaki Ozasa; Susumu Sato; Tomoko Funazo; Yuichi Sakamori; Takashi Nomizo; Kiyomitsu Kuninaga; Tatsuya Ogimoto; Kazutaka Hosoya; Masatoshi Yamazoe; Takahiro Tsuji; Hironori Yoshida; Ryo Itotani; Kentaro Ueno; Young Hak Kim; Shigeo Muro; Toyohiro Hirai

  Scientific reports, 06 Feb. 2023, Peer-reviewed

  
• Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer.

  Yuki Katayama; Tadaaki Yamada; Keiko Tanimura; Shinsaku Tokuda; Kenji Morimoto; Soichi Hirai; Yohei Matsui; Ryota Nakamura; Masaki Ishida; Hayato Kawachi; Kazue Yoneda; Kazutaka Hosoya; Takahiro Tsuji; Hiroaki Ozasa; Akihiro Yoshimura; Masahiro Iwasaku; Young Hak Kim; Mano Horinaka; Toshiyuki Sakai; Takahiro Utsumi; Shinsuke Shiotsu; Takayuki Takeda; Ryohei Katayama; Koichi Takayama

  NPJ precision oncology, 26 Jan. 2023, Peer-reviewed

  
• Salvage Surgery After Immune Checkpoint Inhibitors for Advanced Non-Small Cell Lung Cancer: Potential Association Between Immune-Related Adverse Events and Longer Survival.

  Shunichi Nagata; Masatsugu Hamaji; Hiroaki Ozasa; Yoshito Yamada; Akihiro Ohsumi; Hiroshi Date

  Clinical lung cancer, Jul. 2022, Peer-reviewed

  
• [A Case of Recurrent Gallbladder Cancer with a Complete Response to S-1 Alternate-Day Administration].

  Ryuichi Eto; Hiroki Nakatsu; Hiroaki Ozasa; Ryoichi Shimizu

  Gan to kagaku ryoho. Cancer & chemotherapy, Jan. 2016

  
• Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer.

  Noriko Kishi; Yukinori Matsuo; Takashi Shintani; Masakazu Ogura; Takamasa Mitsuyoshi; Norio Araki; Kota Fujii; Setsuko Okumura; Kiyoshi Nakamatsu; Takahiro Kishi; Tomoko Atsuta; Takashi Sakamoto; Shuji Ohtsu; Tomohiro Katagiri; Masaru Narabayashi; Satsuki Fujishiro; Yusuke Iizuka; Hiroaki Ozasa; Toyohiro Hirai; Takashi Mizowaki

  Journal of radiation research, 20 Jan. 2023, Peer-reviewed

  
• Outcomes of immune checkpoint inhibitors for postoperative recurrence of non-small cell lung cancer.

  Itsuki Yuasa; Masatsugu Hamaji; Hiroaki Ozasa; Yuichi Sakamori; Hironori Yoshida; Yojiro Yutaka; Toshi Menju; Toyohiro Hirai; Hiroshi Date

  General thoracic and cardiovascular surgery, Sep. 2023, Peer-reviewed

  
• Combination bezafibrate and nivolumab treatment of patients with advanced non-small cell lung cancer.

  Kentaro Tanaka; Kenji Chamoto; Sho Saeki; Ryusuke Hatae; Yuki Ikematsu; Kazuko Sakai; Nobuhisa Ando; Kazuhiro Sonomura; Shinsuke Kojima; Masanori Taketsuna; Young Hak Kim; Hironori Yoshida; Hiroaki Ozasa; Yuichi Sakamori; Tomoko Hirano; Fumihiko Matsuda; Toyohiro Hirai; Kazuto Nishio; Takuro Sakagami; Masanori Fukushima; Yoichi Nakanishi; Tasuku Honjo; Isamu Okamoto

  Science translational medicine, 14 Dec. 2022, Peer-reviewed

  
• Yes-associated protein 1 mediates initial cell survival during lorlatinib treatment through AKT signaling in ROS1-rearranged lung cancer.

  Masatoshi Yamazoe; Hiroaki Ozasa; Takahiro Tsuji; Tomoko Funazo; Hiroshi Yoshida; Kentaro Hashimoto; Kazutaka Hosoya; Tatsuya Ogimoto; Hitomi Ajimizu; Hironori Yoshida; Ryo Itotani; Yuichi Sakamori; Kiyomitsu Kuninaga; Wataru Aoki; Toyohiro Hirai

  Cancer science, Feb. 2023, Peer-reviewed, Corresponding author

  
• Sarcomatoid malignant pleural mesothelioma treated with nivolumab: A case series.

  Kentaro Hashimoto; Hiroaki Ozasa; Akihiko Yoshizawa; Hiroshi Yoshida; Tatsuya Ogimoto; Kazutaka Hosoya; Masatoshi Yamazoe; Hitomi Ajimizu; Tomoko Funazo; Hironori Yoshida; Yuichi Sakamori; Toyohiro Hirai

  Oncology letters, Nov. 2022, Peer-reviewed, Corresponding author

  
• Usefulness of pro-gastrin-releasing peptide as a predictor of the incidence of brain metastasis and effect of prophylactic cranial irradiation in patients with limited-stage small-cell lung cancer.

  Kazuihto Ueki; Yukinori Matsuo; Noriko Kishi; Masahiro Yoneyama; Hironori Yoshida; Yuichi Sakamori; Hiroaki Ozasa; Toyohiro Hirai; Takashi Mizowaki

  Journal of radiation research, 19 Jul. 2022, Peer-reviewed

  Access this paper :

  
• Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer.

  Hitomi Ajimizu; Hiroaki Ozasa; Susumu Sato; Tomoko Funazo; Yuichi Sakamori; Takashi Nomizo; Kiyomitsu Kuninaga; Tatsuya Ogimoto; Kazutaka Hosoya; Masatoshi Yamazoe; Takahiro Tsuji; Hironori Yoshida; Ryo Itotani; Kentaro Ueno; Young Hak Kim; Shigeo Muro; Toyohiro Hirai

  Scientific reports, 08 Dec. 2021, Peer-reviewed

  
• PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade.

  Hironori Yoshida; Takashi Nomizo; Hiroaki Ozasa; Takahiro Tsuji; Tomoko Funazo; Yuto Yasuda; Hitomi Ajimizu; Masatoshi Yamazoe; Kiyomitsu Kuninaga; Tatsuya Ogimoto; Kazutaka Hosoya; Ryo Itotani; Yuichi Sakamori; Young Hak Kim; Toyohiro Hirai

  European journal of cancer (Oxford, England : 1990), Feb. 2021, Peer-reviewed, Corresponding author

  
• Thyroid metastasis of pulmonary adenocarcinoma with EGFR G719A mutation: Genetic confirmation with liquid-based cytology specimens.

  Yosuke Yamada; Hiroyuki Shirahase; Mika Fukiya; Akihiko Yoshizawa; Sachiko Minamiguchi; Hiroaki Ozasa; Hironori Haga

  Cytopathology : official journal of the British Society for Clinical Cytology, May 2021, Peer-reviewed

  Access this paper :

  
• Paratracheal Middle Mediastinal Thymic Carcinomas.

  Ryo Nakanobo; Masatsugu Hamaji; Akihiro Ohsumi; Sho Koyasu; Hironori Yoshida; Hiroaki Ozasa; Masahide Isowa; Naoki Nakajima; Akihiko Yoshizawa; Hiroshi Date

  The Annals of thoracic surgery, Jul. 2020, Peer-reviewed

  Access this paper :

  
• A Randomized Phase II Study of Maintenance Bevacizumab, Pemetrexed or Bevacizumab Plus Pemetrexed for Advanced Non-squamous Non-small Cell Lung Cancer.

  Hironori Yoshida; Young Hak Kim; Yuichi Sakamori; Hiroki Nagai; Hiroaki Ozasa; Toshihiko Kaneda; Hiroshige Yoshioka; Hiroaki Nakagawa; Keisuke Tomii; Asuka Okada; Kenichi Yoshimura; Masataka Hirabayashi; Toyohiro Hirai

  Anticancer research, May 2020, Peer-reviewed

  
• Salvage thoracoscopic resection after nivolumab for stage IV.

  Masatsugu Hamaji; Hiroaki Ozasa; Akihiko Yoshizawa; Hiroshi Date

  Asian cardiovascular & thoracic annals, May 2020, Peer-reviewed

  
• Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model.

  Tomoko Funazo; Takahiro Tsuji; Hiroaki Ozasa; Koh Furugaki; Yasushi Yoshimura; Tetsuya Oguri; Hitomi Ajimizu; Yuto Yasuda; Takashi Nomizo; Yuichi Sakamori; Hironori Yoshida; Young Hak Kim; Toyohiro Hirai

  Molecular cancer therapeutics, Jun. 2020, Peer-reviewed, Corresponding author

  
• MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-XL expression.

  Yuto Yasuda; Hiroaki Ozasa; Young Hak Kim; Masatoshi Yamazoe; Hitomi Ajimizu; Tomoko Yamamoto Funazo; Takashi Nomizo; Takahiro Tsuji; Hironori Yoshida; Yuichi Sakamori; Naoki Nakajima; Toshi Menju; Akihiko Yoshizawa; Hiroshi Date; Toyohiro Hirai

  Cell death & disease, 09 Mar. 2020, Peer-reviewed, Corresponding author

  Access this paper :

  
• Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy.

  Ryusuke Hatae; Kenji Chamoto; Young Hak Kim; Kazuhiro Sonomura; Kei Taneishi; Shuji Kawaguchi; Hironori Yoshida; Hiroaki Ozasa; Yuichi Sakamori; Maryam Akrami; Sidonia Fagarasan; Izuru Masuda; Yasushi Okuno; Fumihiko Matsuda; Toyohiro Hirai; Tasuku Honjo

  JCI insight, 30 Jan. 2020, Peer-reviewed

  Access this paper :

  
• YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation.

  Takahiro Tsuji; Hiroaki Ozasa; Wataru Aoki; Shunsuke Aburaya; Tomoko Yamamoto Funazo; Koh Furugaki; Yasushi Yoshimura; Masatoshi Yamazoe; Hitomi Ajimizu; Yuto Yasuda; Takashi Nomizo; Hironori Yoshida; Yuichi Sakamori; Hiroaki Wake; Mitsuyoshi Ueda; Young Hak Kim; Toyohiro Hirai

  Nature communications, 03 Jan. 2020, Peer-reviewed, Corresponding author

  Access this paper :

  
• Management and Outcomes of Newly Diagnosed Non-Small Cell Lung Cancer Patients with Brain Metastases: A Real-World Study in Japan.

  Hironori Yoshida; Young Hak Kim; Shigeaki Iwatsubo; Chikara Sakaguchi; Yuichi Sakamori; Hiroki Nagai; Hiroaki Ozasa; Tadashi Mio; Toyohiro Hirai

  Oncology, 2020, Peer-reviewed

  
• Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab.

  Tomoko Yamamoto Funazo; Takashi Nomizo; Hiroaki Ozasa; Takahiro Tsuji; Yuto Yasuda; Hironori Yoshida; Yuichi Sakamori; Hiroki Nagai; Toyohiro Hirai; Young Hak Kim

  Scientific reports, 19 Nov. 2019, Peer-reviewed, Corresponding author

  Access this paper :

  
• Effectiveness of Nivolumab on Sarcomatoid Malignant Pleural Mesothelioma With Eosinophilia and Eosinophilic Pleural Effusion.

  Masatoshi Yamazoe; Hiroaki Ozasa; Young Hak Kim

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, Nov. 2019, Peer-reviewed, Corresponding author

  
• Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model.

  Takahiro Tsuji; Hiroaki Ozasa; Wataru Aoki; Shunsuke Aburaya; Tomoko Funazo; Koh Furugaki; Yasushi Yoshimura; Hitomi Ajimizu; Ryoko Okutani; Yuto Yasuda; Takashi Nomizo; Kiyoshi Uemasu; Koichi Hasegawa; Hironori Yoshida; Yoshitaka Yagi; Hiroki Nagai; Yuichi Sakamori; Mitsuyoshi Ueda; Toyohiro Hirai; Young Hak Kim

  Molecular cancer research : MCR, Jan. 2019, Peer-reviewed, Corresponding author

  
• PD-L1 Expression in Small Cell Lung Cancer.

  Yuto Yasuda; Hiroaki Ozasa; Young Hak Kim

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, Mar. 2018, Peer-reviewed

  
• Nivolumab in non-small-cell lung cancer with EGFR mutation

  H. Yoshida; Y.H. Kim; H. Ozasa; H. Nagai; Y. Sakamori; T. Tsuji; T. Nomizo; Y. Yasuda; T. Funazo; T. Hirai

  Annals of Oncology, Mar. 2018, Peer-reviewed

  
• Efficacy of Ceritinib After Alectinib for ALK-positive Non-small Cell Lung Cancer.

  Hironori Yoshida; Young Hak Kim; Hiroaki Ozasa; Yuichi Sakamori; Takahiro Tsuji; Takashi Nomizo; Yuto Yasuda; Tomoko Yamamoto; Hitomi Ajimizu; Toyohiro Hirai

  In vivo (Athens, Greece), 2018, Peer-reviewed

  
• Retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease.

  Yuto Yasuda; Takashi Nomizo; Hiroaki Ozasa; Tomoko Funazo; Takahiro Tsuji; Hironori Yoshida; Yuichi Sakamori; Hiroki Nagai; Tomohiro Handa; Takeshi Kubo; Young Hak Kim

  Molecular and clinical oncology, Oct. 2017, Peer-reviewed

  
• Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer.

  Takahiro Tsuji; Yuichi Sakamori; Hiroaki Ozasa; Yoshitaka Yagi; Hitomi Ajimizu; Yuto Yasuda; Tomoko Funazo; Takashi Nomizo; Hironori Yoshida; Hiroki Nagai; Ken Maeno; Tetsuya Oguri; Toyohiro Hirai; Young Hak Kim

  Oncotarget, 22 Sep. 2017, Peer-reviewed, Corresponding author

  Access this paper :

  
• Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib.

  Nobukazu Agatsuma; Yuto Yasuda; Hiroaki Ozasa

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, Sep. 2017, Peer-reviewed

  
• Successful oral desensitization with crizotinib after crizotinib-induced hepatitis in an anaplastic lymphoma kinase-rearranged non-small-cell lung cancer patient: A case report.

  Yuto Yasuda; Yasuyo Nishikawa; Yuichi Sakamori; Makoto Terao; Kentaro Hashimoto; Tomoko Funazo; Takashi Nomizo; Takahiro Tsuji; Hironori Yoshida; Hiroki Nagai; Hiroaki Ozasa; Toyohiro Hirai; Young Hak Kim

  Molecular and clinical oncology, Aug. 2017, Peer-reviewed

  
• EGFR T790M Detection in Circulating Tumor DNA from Non-small Cell Lung Cancer Patients Using the PNA-LNA Clamp Method.

  Hironori Yoshida; Young Hak Kim; Hiroaki Ozasa; Hiroki Nagai; Yuichi Sakamori; Takahiro Tsuji; Takashi Nomizo; Tomoko Funazo; Yuto Yasuda; Toyohiro Hirai

  Anticancer research, May 2017, Peer-reviewed

  
• Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients.

  Takashi Nomizo; Hiroaki Ozasa; Takahiro Tsuji; Tomoko Funazo; Yuto Yasuda; Hironori Yoshida; Yoshitaka Yagi; Yuichi Sakamori; Hiroki Nagai; Toyohiro Hirai; Young Hak Kim

  Scientific reports, 23 Mar. 2017, Peer-reviewed, Corresponding author

  Access this paper :

  
• Albumin-bound paclitaxel for the treatment of refractory or relapsed small-cell lung cancer.

  Hironori Yoshida; Young Hak Kim; Hiroaki Ozasa; Hiroki Nagai; Yuichi Sakamori; Takashi Nakaoku; Yoshitaka Yagi; Takahiro Tsuji; Takashi Nomizo; Michiaki Mishima

  Molecular and clinical oncology, Jul. 2016, Peer-reviewed

  
• Response to chemotherapy with carboplatin plus albumin-bound paclitaxel in a patient with lymphoepithelioma-like thymic carcinoma: A case report.

  Hiroshi Shima; Hiroaki Ozasa; Takahiro Tsuji; Hitomi Ajimizu; Takashi Nomizo; Yoshitaka Yagi; Yuichi Sakamori; Hiroki Nagai; Sachiko Minamiguchi; Young Hak Kim; Michiaki Mishima

  Molecular and clinical oncology, May 2016, Peer-reviewed

  
• Reversal of c-MET-mediated Resistance to Cytotoxic Anticancer Drugs by a Novel c-MET Inhibitor TAS-115.

  Eiji Kunii; Hiroaki Ozasa; Tetsuya Oguri; Ken Maeno; Satoshi Fukuda; Takehiro Uemura; Osamu Takakuwa; Hirotsugu Ohkubo; Masaya Takemura; Akio Niimi

  Anticancer research, Oct. 2015, Peer-reviewed

  
• Organic cation transporter OCT6 mediates cisplatin uptake and resistance to cisplatin in lung cancer.

  Eiji Kunii; Tetsuya Oguri; Daishi Kasai; Hiroaki Ozasa; Takehiro Uemura; Osamu Takakuwa; Hirotsugu Ohkubo; Masaya Takemura; Ken Maeno; Akio Niimi

  Cancer chemotherapy and pharmacology, May 2015, Peer-reviewed

  
• Effect of liver toxicity on clinical outcome of patients with non-small-cell lung cancer treated with pemetrexed.

  Yuichi Sakamori; Young Hak Kim; Hironori Yoshida; Takashi Nakaoku; Hiroki Nagai; Yoshitaka Yagi; Hiroaki Ozasa; Michiaki Mishima

  Molecular and clinical oncology, Mar. 2015, Peer-reviewed

  
• Successful treatment with carboplatin and nanoparticle albumin-bound paclitaxel in a patient with pulmonary spindle cell carcinoma.

  Takahiro Tsuji; Young Hak Kim; Hiroaki Ozasa; Yuichi Sakamori; Hiroki Nagai; Hitomi Ajimizu; Yoshitaka Yagi; Atsuyuki Furukawa; Hironori Haga; Michiaki Mishima

  Respiratory medicine case reports, 2015, Peer-reviewed

  Access this paper :

  
• Significance of c-MET overexpression in cytotoxic anticancer drug-resistant small-cell lung cancer cells.

  Hiroaki Ozasa; Tetsuya Oguri; Ken Maeno; Osamu Takakuwa; Eiji Kunii; Yoshitaka Yagi; Takehiro Uemura; Daishi Kasai; Mikinori Miyazaki; Akio Niimi

  Cancer science, Aug. 2014, Peer-reviewed, Lead author

  
• Analgesic effect of switching from oral opioids to a once-a-day fentanyl citrate transdermal patch in patients with lung cancer.

  Osamu Takakuwa; Tetsuya Oguri; Ken Maeno; Midori Yokoyama; Hisatoshi Hijikata; Takehiro Uemura; Hiroaki Ozasa; Hirotsugu Ohkubo; Mikinori Miyazaki; Akio Niimi

  The American journal of hospice & palliative care, Nov. 2013, Peer-reviewed

  
• High-dose crizotinib for brain metastases refractory to standard-dose crizotinib.

  Young Hak Kim; Hiroaki Ozasa; Hiroki Nagai; Yuichi Sakamori; Hironori Yoshida; Yoshitaka Yagi; Takashi Nakaoku; Michiaki Mishima

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, Sep. 2013, Peer-reviewed

  
• Therapeutic strategy for non-small-cell lung cancer patients with brain metastases (Review).

  Young Hak Kim; Hiroki Nagai; Hiroaki Ozasa; Yuichi Sakamori; Michiaki Mishima

  Biomedical reports, Sep. 2013, Peer-reviewed

  
• Involvement of intermediate filament nestin in cell growth of small-cell lung cancer.

  Osamu Takakuwa; Ken Maeno; Eiji Kunii; Hiroaki Ozasa; Hisatoshi Hijikata; Takehiro Uemura; Daishi Kasai; Hirotsugu Ohkubo; Mikinori Miyazaki; Tetsuya Oguri; Akio Niimi

  Lung cancer (Amsterdam, Netherlands), Aug. 2013, Peer-reviewed

  
• Thymidylate synthase gene copy number as a predictive marker for response to pemetrexed treatment of lung adenocarcinoma.

  Daishi Kasai; Hiroaki Ozasa; Tetsuya Oguri; Mikinori Miyazaki; Takehiro Uemura; Osamu Takakuwa; Eiji Kunii; Hirotsugu Ohkubo; Ken Maeno; Akio Niimi

  Anticancer research, May 2013, Peer-reviewed

  
• Disease flare after discontinuation of crizotinib in anaplastic lymphoma kinase-positive lung cancer.

  Yuka Kuriyama; Young Hak Kim; Hiroki Nagai; Hiroaki Ozasa; Yuichi Sakamori; Michiaki Mishima

  Case reports in oncology, 2013, Peer-reviewed

  
• Phase II study of pemetrexed and erlotinib in pretreated nonsquamous, non-small-cell lung cancer patients without an EGFR mutation.

  Young Hak Kim; Takashi Nishimura; Hiroaki Ozasa; Hiroki Nagai; Yuichi Sakamori; Toshiyuki Iwata; Hironobu Sunadome; Tomoko Nishimura; Michiaki Mishima

  Chemotherapy, 2013, Peer-reviewed

  
• Preclinical rationale for synergistic interaction of pemetrexed and cytotoxic nucleoside analogues.

  Tetsuya Oguri; Hiroaki Ozasa; Takehiro Uemura; Osamu Takakuwa; Eiji Kunii; Daishi Kasai; Hirotsugu Ohkubo; Mikinori Miyazaki; Ken Maeno; Shigeki Sato

  Oncology letters, Sep. 2012, Peer-reviewed

  
• A case of carcinomatous meningitis despite prophylactic cranial irradiation in small cell lung cancer during treatment with amrubicin.

  Tetsuya Oguri; Takehiro Uemura; Eiji Kunii; Hiroaki Ozasa; Hirotsugu Ohkubo; Mikinori Miyazaki; Ken Maeno; Shigeki Sato

  Oncology letters, Aug. 2012, Peer-reviewed

  
• S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type.

  Yuki Tomita; Tetsuya Oguri; Osamu Takakuwa; Makoto Nakao; Eiji Kunii; Takehiro Uemura; Hiroaki Ozasa; Mikinori Miyazaki; Ken Maeno; Shigeki Sato

  Oncology letters, Feb. 2012, Peer-reviewed

  
• C609T polymorphism of NAD(P)H quinone oxidoreductase 1 as a predictive biomarker for response to amrubicin.

  Osamu Takakuwa; Tetsuya Oguri; Hiroaki Ozasa; Takehiro Uemura; Eiji Kunii; Daishi Kasai; Mikinori Miyazaki; Ken Maeno; Shigeki Sato

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, Nov. 2011, Peer-reviewed

  
• Over-expression of MDR1 in amrubicinol-resistant lung cancer cells.

  Osamu Takakuwa; Tetsuya Oguri; Hiroaki Ozasa; Takehiro Uemura; Daishi Kasai; Mikinori Miyazaki; Ken Maeno; Shigeki Sato

  Cancer chemotherapy and pharmacology, Sep. 2011, Peer-reviewed

  
• ABCC11/MRP8 confers pemetrexed resistance in lung cancer.

  Takehiro Uemura; Tetsuya Oguri; Hiroaki Ozasa; Osamu Takakuwa; Mikinori Miyazaki; Ken Maeno; Shigeki Sato; Ryuzo Ueda

  Cancer science, Nov. 2010, Peer-reviewed

  
• Significance of thymidylate synthase for resistance to pemetrexed in lung cancer.

  Hiroaki Ozasa; Tetsuya Oguri; Takehiro Uemura; Mikinori Miyazaki; Ken Maeno; Shigeki Sato; Ryuzo Ueda

  Cancer science, Jan. 2010, Peer-reviewed, Lead author

  
• Efficacy of S-1 monotherapy for non-small cell lung cancer after the failure of two or more prior chemotherapy regimens.

  Osamu Takakuwa; Tetsuya Oguri; Ken Maeno; Hiroaki Ozasa; Yasuhito Iwashima; Mikinori Miyazaki; Hideharu Kunii; Yuko Takano; Toshiyuki Mori; Shigeki Sato; Ryuzo Ueda

  Oncology letters, Jan. 2010, Peer-reviewed

  
• Small-cell lung cancer arising after chemotherapy for a patient with lymphoma of pulmonary mucosa-associated lymphoid tissue-a case report.

  Makoto Nakao; Tetsuya Oguri; Ken Maeno; Shigeru Kusumoto; Chiharu Ota; Osamu Takakuwa; Takehiro Uemura; Hiroaki Ozasa; Yasuhito Iwashima; Mikinori Miyazaki; Takeo Kutsuna; Atsushi Nakamura; Hiroshi Inagaki; Shigeki Sato; Ryuzo Ueda

  Gan to kagaku ryoho. Cancer & chemotherapy, Oct. 2009, Peer-reviewed

  
• ABCC10/MRP7 is associated with vinorelbine resistance in non-small cell lung cancer.

  Yuji Bessho; Tetsuya Oguri; Hiroaki Ozasa; Takehiro Uemura; Hideo Sakamoto; Mikinori Miyazaki; Ken Maeno; Shigeki Sato; Ryuzo Ueda

  Oncology reports, Jan. 2009, Peer-reviewed

  
• MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer.

  Tetsuya Oguri; Hiroaki Ozasa; Takehiro Uemura; Yuji Bessho; Mikinori Miyazaki; Ken Maeno; Hiroyoshi Maeda; Shigeki Sato; Ryuzo Ueda

  Molecular cancer therapeutics, May 2008, Peer-reviewed

  
• The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer.

  Tetsuya Oguri; Hiroyuki Achiwa; Hideki Muramatsu; Hiroaki Ozasa; Shigeki Sato; Shigeki Shimizu; Hideko Yamazaki; Tadaaki Eimoto; Ryuzo Ueda

  Cancer letters, 18 Oct. 2007, Peer-reviewed

  
• Effects of FOXP3 gene polymorphism in sarcoidosis patients.

  Yuko Takano; Takashi Niimi; Shigeki Sato; Noriko Yamada; Hiroyuki Achiwa; Hiroyoshi Maeda; Tetsuya Oguri; Yuji Bessho; Mikinori Miyazaki; Ken Maeno; Hiroaki Ozasa; Ryuzo Ueda

  Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, Sep. 2007, Peer-reviewed

  
• MRP8/ABCC11 directly confers resistance to 5-fluorouracil.

  Tetsuya Oguri; Yuji Bessho; Hiroyuki Achiwa; Hiroaki Ozasa; Ken Maeno; Hiroyoshi Maeda; Shigeki Sato; Ryuzo Ueda

  Molecular cancer therapeutics, Jan. 2007, Peer-reviewed

  

Misc.

• Physiological Uptake of 18F-AraG immunoPET in Non-Small Cell Lung Cancer Patients in Japan

  Tomomi Nobashi; Yoichi Shimizu; Kanae Miyake; Hitomi Ajimizu; Takashi Nomizo; Hironori Yoshida; Hiroaki Ozasa; Ryo Sakamoto; Jelena Levi; Yuji Nakamoto

  JOURNAL OF NUCLEAR MEDICINE, 01 Jun. 2024

  
• ALK肺がんにおける分子標的薬に対するTEAD阻害薬の併用効果のバイオマーカー探索(Biomarkers for Efficacy of TEAD Inhibitor Combination with Molecularly targeted drugs in ALK Lung Cancer)

  橋本 健太郎; 小笹 裕晃; 島 佑介; 住永 圭一郎; 吉田 寛; 細谷 和貴; 船造 智子; 味水 瞳; 吉田 博徳; 野溝 岳; Tang Tracy T.; 平井 豊博; 小笹 裕晃

  日本癌学会総会記事, Sep. 2024

  
• 肺癌肝転移成立の機序からの新規治療因子の探索(Exploration of novel therapeutic factors in the mechanism of establishment of liver metastases in lung cancer)

  吉田 寛; 小笹 裕晃; 味水 瞳; 細谷 和貴; 島 佑介; 住永 圭一郎; 橋本 健太郎; 山本 智子; 野溝 岳; 吉田 博徳; 平井 豊博; 小笹 裕晃

  日本癌学会総会記事, Sep. 2024

  
• 新たな肺腺癌脳転移モデルを用いた抗PD-1/CTLA-4抗体併用療法の有効性と作用機序の検討(Novel Model of Lung Adenocarcinoma Brain Metastasis Reveals Efficacy of Anti-PD-1/CTLA-4 Combination Therapy)

  細谷 和貴; 小笹 裕晃; 辻 貴宏; 島 佑介; 住永 圭一郎; 橋本 健太郎; 吉田 寛; 味水 瞳; 船造 智子; 吉田 博徳; 野溝 岳; 和氣 弘明; 平井 豊博; 辻 貴宏

  日本癌学会総会記事, Sep. 2024

  
• 免疫チェックポイント阻害薬による間質性肺疾患の自覚症状と重症度の関連

  横井 茉里; 米澤 淳; 平 大樹; 半田 知宏; 谷澤 公伸; 中川 俊作; 池見 泰明; 糸谷 涼; 吉田 博徳; 野村 基雄; 村上 孝作; 小笹 裕晃; 武藤 学; 寺田 智祐

  日本臨床免疫学会総会プログラム・抄録集, Oct. 2023

  
• オンコマインでドライバー遺伝子検出されず,Foundation OneでSCL8A1-ALK融合遺伝子が検出され,アレクチニブが有効であったALK陽性肺腺癌の1例

  名取 大輔; 橋本 健太郎; 吉田 寛; 味水 瞳; 野溝 岳; 吉田 博徳; 小笹 裕晃; 平井 豊博; 吉岡 正博; 金井 雅史; 武藤 学

  肺癌, Oct. 2023

  
• ALK陽性肺癌の1次治療におけるロルラチニブの果たすべき役割とは? 最新のフォローアップデータを交えて

  小笹 裕晃

  肺癌, Oct. 2023

  
• 臨床III期N2非小細胞肺癌の治療戦略 臨床III期N2非小細胞肺癌に対する術前化学放射線療法

  伊達 洋至; 小笹 裕晃; 岸 徳子; 西川 滋人; 毛受 暁史

  肺癌, Oct. 2023

  
• 新規TEAD1阻害薬VT103とDabrafenibの併用はBRAF V600E変異肺癌細胞株のアポトーシスを亢進させる(Novel TEAD1 inhibitor VT103 plus dabrafenib promotes apoptosis in BRAF V600E mutated lung adenocarcinoma cell lines)

  細谷 和貴; 小笹 裕晃; 橋本 健太郎; 吉田 寛; 大木元 達也; 味水 瞳; 船造 智子; 吉田 博徳; 野溝 岳; 辻 貴宏; Tracy Tang T.; 平井 豊博

  日本癌学会総会記事, Sep. 2023

  
• 新規TEAD1阻害薬VT103はALK陽性肺癌細胞株に対するTKIの効果を増幅する(Novel TEAD1 inhibitor VT103 may enhance efficacy of ALK-TKI in lung cancer cell line in vitro and in vivo)

  橋本 健太郎; 小笹 裕晃; 山添 正敏; 吉田 寛; 大木元 達也; 細谷 和貴; 船造 智子; 味水 瞳; 吉田 博徳; 野溝 岳; Tang Tracy T.; 平井 豊博

  日本癌学会総会記事, Sep. 2023

  
• 肺癌転移性脳腫瘍の生体内観察モデルを用いた,新規治療薬の検討

  小笹 裕晃; 細谷 和貴; 辻 貴宏; 味水 瞳; 和氣 弘明; 平井 豊博

  日本呼吸器学会誌, Mar. 2023

  
• YAP1はAKTシグナルを介してROS1肺癌におけるROS1阻害薬からの初期生存に関与する(YAP1 mediates initial cell survival during lorlatinib treatment via AKT signaling in ROS1-rearranged lung cancer)

  山添 正敏; 小笹 裕晃; 辻 貴宏; 船造 智子; 吉田 寛; 橋本 健太郎; 細谷 和貴; 大木元 達也; 味水 瞳; 吉田 博徳; 糸谷 涼; 阪森 優一; 國永 清光; 平井 豊博

  日本癌学会総会記事, Sep. 2022

  
• ALK融合遺伝子陽性肺がんにおけるEGFRシグナル活性化を介したロルラチニブ初期治療抵抗性の解明とその克服(Adaptive resistance to lorlatinib by EGFR activation in ALK-rearranged non-small cell lung cancer cells)

  片山 勇輝; 谷村 恵子; 森本 健司; 堀中 真野; 酒井 敏行; 小笹 裕晃; 山田 忠明

  日本癌学会総会記事, Sep. 2022

  
• 転移性脳腫瘍モデルを用いた転移制御因子の探索

  辻 貴宏; 和氣 弘明; 進藤 麻理子; 加藤 大輔; 大木元 達也; 細谷 和貴; 味水 瞳; 小笹 裕晃; 平井 豊博

  肺癌, Oct. 2021

  
• 二光子顕微鏡による肺癌肝転移モデルの観察

  味水 瞳; 小笹 裕晃; 辻 貴宏; 橋本 健太郎; 吉田 寛; 大木元 達也; 細谷 和貴; 山添 正敏; 船造 智子; 糸谷 涼; 吉田 博徳; 和氣 弘明; 平井 豊博

  日本癌学会総会記事, Sep. 2021

  
• TEAD遺伝子の一塩基多型はEGFR肺癌患者においてEGFRチロシンキナーゼ阻害薬による無増悪生存期間に影響する

  山添 正敏; 小笹 裕晃; 大木元 達也; 細谷 和貴; 味水 瞳; 山本 智子; 辻 貴宏; 糸谷 涼; 吉田 博徳; 阪森 優一; 野溝 岳; 吉田 寛; 橋本 健太郎; 平井 豊博

  日本癌学会総会記事, Sep. 2021

  
• BRAF V600E変異陽性肺癌の分子標的薬耐性に上皮間葉転換(EMT)が関与する

  細谷 和貴; 小笹 裕晃; 橋本 健太郎; 吉田 寛; 大木元 達也; 山添 正敏; 味水 瞳; 船造 智子; 辻 貴宏; 吉田 博徳; 阪森 優一; 平井 豊博

  日本癌学会総会記事, Sep. 2021

  
• CD47のSNPsが肺癌のニボルマブの治療効果に影響を与える

  大木元 達也; 小笹 裕晃; 橋本 健太郎; 吉田 寛; 細谷 和貴; 山添 正敏; 味水 瞳; 船造 智子; 辻 貴宏; 吉田 博徳; 阪森 優一; 平井 豊博

  日本癌学会総会記事, Sep. 2021

  
• PD-L1高発現のSTK11/TP53/KRAS変異陽性肺腺癌に対して免疫チェックポイント阻害剤を投与した症例

  吉田 博徳; 橋本 健太郎; 吉田 寛; 味水 瞳; 糸谷 涼; 阪森 優一; 小笹 裕晃; 平井 豊博

  気管支学, Jun. 2023

  
• 当院における胸部悪性腫瘍に対するComprehensive Genomic Profilingの有用性の検証

  住永 圭一郎; 吉田 博徳; 名取 大輔; 島 佑介; 味水 瞳; 野溝 岳; 小笹 裕晃; 阪森 優一; 吉岡 正博; 金井 雅史; 武藤 学; 平井 豊博

  肺癌, Oct. 2023

  
• 多発性の中心型早期肺癌に対し複数回の光線力学的治療を施行した1例

  時任 寛行; 吉田 博徳; 阪森 優一; 小笹 裕晃; 平井 豊博

  気管支学, Sep. 2022

  
• YAP1やその他の因子はEGFR遺伝子変異陽性肺癌の初期耐性機序と関連する(YAP1 and other factors are associated with initial resistance mechanisms in EGFR mutation-positive lung cancer)

  大木元 達也; 小笹 裕晃; 橋本 健太郎; 吉田 寛; 細谷 和貴; 山添 正敏; 味水 瞳; 船造 智子; 辻 貴宏; 吉田 博徳; 阪森 優一; 平井 豊博

  日本癌学会総会記事, Sep. 2022

  
• 患者由来BRAF V600E変異陽性肺癌細胞株に対し、新規TEAD1阻害薬VT103がアポトーシスを促進する(Novel TEAD1 inhibitor VT103 promotes apoptosis in patient-derived BRAF V600E mutated lung adenocarcinoma cell lines)

  細谷 和貴; 小笹 裕晃; 橋本 健太郎; 吉田 寛; 大木元 達也; 山添 正敏; 味水 瞳; 船造 智子; 辻 貴宏; 吉田 博徳; 阪森 優一; Tracy Tang T.; 平井 豊博

  日本癌学会総会記事, Sep. 2022

  
• 非小細胞肺癌に対する免疫チェックポイント阻害治療中にoligoprogressionを示した病変に対し,外科切除を行った3例

  細谷和貴; 吉田博徳; 小笹裕晃; 糸谷涼; 阪森優一; 金永学; 平井豊博; 濱路政嗣; 吉澤明彦

  肺癌(Web), 2021

  
• BRAF陽性肺癌にDabrafenib/Trametinibが投与された4例の検討

  藤原直樹; 山添正敏; 辻貴宏; 吉田博徳; 小笹裕晃; 金永学; 平井豊博; 阪森優一

  肺癌(Web), 2020

  
• 肺がん患者由来細胞樹立による,ALK陽性肺がん耐性機序解明の取り組み

  山添正敏; 辻貴宏; 小笹裕晃; 阪森優一; 吉田博徳; 金永学; 平井豊博

  肺癌(Web), 2019

  
• Nivolumabが投与された大細胞神経内分泌癌(LCNEC)4例の検討

  島佑介; 阪森優一; 吉田博徳; 小笹裕晃; 平井豊博; 金永学; 島佑介; 阪森優一; 吉田博徳; 小笹裕晃; 平井豊博; 金永学

  肺癌(Web), 2019

  
• 化学療法とオシメルチニブの併用が効果的であったEGFR変異陽性肺癌の1例

  大井昌寛; 吉田博徳; 阪森優一; 小笹裕晃; 平井豊博; 金永学

  肺癌(Web), 2018

  
• 局所放射線治療後にNivolumabの全身奏功を認めた肺腺癌の1例

  菊池悠次郎; 味水瞳; 小笹裕晃; 阪森優一; 金永学

  肺癌(Web), 2018

  
• 当院におけるオシメルチニブの使用経験

  吉田博徳; 船造智子; 安田有斗; 野溝岳; 辻貴宏; 阪森優一; 永井宏樹; 小笹裕晃; 金永学

  肺癌(Web), 2017

  
• 免疫チェックポイント阻害剤の副作用マネージメント

  永井宏樹; 船造智子; 安田有斗; 野溝岳; 辻貴宏; 吉田博徳; 阪森優一; 小笹裕晃; 金永学

  肺癌(Web), 2017

  
• Activation of YAP1 confers ROS1 inhibitor resistance in ROS1-rearranged lung cancer

  Masatoshi Yamazoe; Hiroaki Ozasa; Tetsuya Ohgimoto; Kazutaka Hosoya; Hitomi Ajimizu; Tomoko Funazo; Yuto Yasuda; Takahiro Tsuji; Hironori Yoshida; Ryo Itotani; Yuichi Sakamori; Young Hak Kim; Hirai Toyohiro

  CANCER RESEARCH, Jul. 2021, Corresponding author

  
• Activation of YAP1 confers ROS1 inhibitor resistance in ROS1-rearranged lung cancer

  Masatoshi Yamazoe; Hiroaki Ozasa; Tatsuya Ogimoto; Kazutaka Hosoya; Hitomi Ajimizu; Yuto Yasuda; Tomoko Funazo; Takahiro Tsuji; Hironori Yoshida; Yuichi Sakamori; Young Hak Kim; Toyohiro Hirai

  CANCER SCIENCE, Feb. 2021, Corresponding author

  
• YAP1は抗Apoptosis因子Mcl-1とBcl-xLの発現調節を介して,ALK陽性肺癌細胞の初期生存を仲介する

  辻貴宏; 小笹裕晃; 青木航; 油屋駿介; 船造智子; 山添正敏; 味水瞳; 安田有斗; 野溝岳; 吉田博徳; 阪森優一; 和氣弘明; 和氣弘明; 植田充美; 平井豊博; 金永学

  日本肺癌学会学術集会号, 2020, Corresponding author

  
• 非小細胞肺癌初回治療における化学療法+免疫チェックポイント阻害剤併用療法の多施設共同後ろ向き観察研究.

  吉田博徳、金永学、岩坪重彰、小笹裕晃、阪森優一、平井豊博、西村尚志、坂口才、野口哲男、三尾直士

  第60回日本肺癌学会学術集会. 大阪, 06 Dec. 2019

  
• Efficacy of MCL1 inhibitor S63845 in small cell lung cancer in vitro and in vivo.

  Yasuda Y, Ozasa H, Tsuji T, Nomizo T, Funazo T, Ajimizu H, Yamazoe M, Yoshida H, Sakamori Y, Hirai T, and Kim YH

  第78回 日本癌学会学術総会 京都, 26 Sep. 2019, Corresponding author

  
• 転移性脳腫瘍の可視化モデル

  辻貴宏、和氣弘明、小笹裕晃、進藤麻理子、味水瞳、山添正敏、安田有斗、阪森優一、野溝岳、金永学、平井豊博

  第78回日本癌学会学術総会, 26 Sep. 2019

  
• ロルラチニブが投与されたALK陽性肺癌4例の検討.

  住永圭一郎、吉田博徳、阪森優一、小笹裕晃、平井豊博、金 永学

  第110回日本肺癌学会関西支部学術集会., 29 Jun. 2019

  
• ABCC11 is involved in resistance to alectinib

  Tomoko Yamamoto Funazo; Hiroaki Ozasa; Takahiro Tsuji; Koh Furugaki; Yasushi Yoshimura; Hitomi Ajimizu; Yuto Yasuda; Takashi Nomizo; Yuichi Sakamori; Hironori Yoshida; Young Hak Kim; Toyohiro Hirai

  AACR Annual Meeting 2019, Apr. 2019, Peer-reviewed, Corresponding author

  
• Association of ALDH7A1 overexpression with chemotherapy resistance and cancer stem cell in lung cancer

  Yuto Yasuda; Yuichi Sakamori; Hiroaki Ozasa; Hitomi Ajimizu; Tetsuya Oguri; Ken Maeno; Takahiro Tsuji; Takashi Nomizo; Tomoko Yamamoto; Hironori Yoshida; Toyohiro Hirai; Young Hak Kim

  AACR Annual Meeting 2019, Apr. 2019, Peer-reviewed

  
• Real-time visualization of brain metastasis in vivo

  Takahiro Tsuji; Hiroaki Wake; Hiroaki Ozasa; Koichiro Haruwaka; Hitomi Ajimizu; Yuto Yasuda; Yuichi Sakamori; Takashi Nomizo; Young Hak Kim; Toyohiro Hirai

  AACR Annual Meeting 2019, Apr. 2019, Peer-reviewed

  
• In vitro and in vivo efficacy of MCL1 inhibitor S63845 in small cell lung cancer

  Yuto Yasuda; Hiroaki Ozasa; Takahiro Tsuji; Takashi Nomizo; Tomoko Yamamoto; Hitomi Ajimizu; Hironori Yoshida; Yuichi Sakamori; Toyohiro Hirai; Young Hak Kim

  AACR Annual Meeting 2019, Apr. 2019, Peer-reviewed, Corresponding author

  
• YAP1 mediates initial survival of alectinib therapy in ALK-rearranged lung cancer via pro-apoptotic protein regulation

  Takahiro Tsuji; Hiroaki Ozasa; Wataru Aoki; Shunsuke Aburaya; Tomoko Funazo; Koh Furugaki; Yasushi Yoshimura; Hitomi Ajimizu; Yuto Yasuda; Takashi Nomizo; Yuichi Sakamori; Hironori Yoshida; Mitsuyoshi Ueda; Young Hak Kim; Toyohiro Hirai

  AACR Annual Meeting 2019, Mar. 2019, Peer-reviewed, Corresponding author

  
• ドライバー変異陰性の非小細胞肺癌に対する2次治療としてのニボルマブとその他の抗癌剤との比較検討

  阪森優一; 味水瞳; 山本智子; 安田有斗; 野溝岳; 辻貴宏; 吉田博徳; 小笹裕晃; 金永学

  第59回日本肺癌学会学術集会., Nov. 2018, Peer-reviewed

  
• Nivolumabに耐性を来たした非小細胞肺癌の臨床的特徴の検討

  吉田博徳; 味水瞳; 山本智子; 安田有斗; 野溝岳; 辻貴宏; 阪森優一; 小笹裕晃; 平井豊博; 金永学

  第59回日本肺癌学会学術集会., Nov. 2018, Peer-reviewed

  
• Clinical impact of hypothyroidism and PD-L1 SNPs in patients with non-small cell lung cancer treated with nivolumab.

  Yamamoto T; Ozasa H; Nomizo T; Ajimizu H; Yasuda Y; Tsuji T; Yoshida H; Nagai H; Sakamori Y; Hirai T; Kim YH

  ESMO 2018 Congress., Oct. 2018, Peer-reviewed, Corresponding author

  
• PD-L1 rs2282055 genotypes are oppositely associated with response to platinum-based chemotherapy and nivolumab treatmen

  Nomizo T; Ozasa H; Tsuji T; Funazo T; Yasuda Y; Yoshida H; Sakamori Y; Hirai T; Kim YH

  第77回 日本癌学会学術総会, Sep. 2018, Peer-reviewed, Corresponding author

  
• Efficacy of MCL1 inhibitor S63845 in small cell lung cancer.

  Yasuda Y; Ozasa H; Tsuji T; Nomizo T; Funazo T; Ajimizu H; Yoshida H; Sakamori Y; Hirai T; Kim YH

  第77回 日本癌学会学術総会, Sep. 2018

  
• ペムブロリズマブ無効でクリゾチニブが著効したPD-L1高発現・ROS1陽性肺癌の一例.

  丸口直人; 吉田博徳; 阪森優一; 小笹裕晃; 平井豊博; 金永学

  第108回日本肺癌学会関西支部学術集会, Jun. 2018, Peer-reviewed

  
• PD-L1 rs2282055 is associated with opposite treatment effect between platinum-based chemotherapy and nivolumab treatment

  Nomizo T; Ozasa H; Tsuji T; Funazo T; Yasuda Y; Yoshida H; Sakamori Y; Hirai T; Kim YH

  AACR Annual Meeting 2018., Apr. 2018, Peer-reviewed

  
• Clinical impact of hypothyroidism and PD-L1 SNPs in patients having non-small cell lung cancer treated with nivolumab

  Funazo T; Ozasa H; Nomizo T; Tsuji T; Yasuda Y; Yoshida H; Sakamori Y; Nagai H; Hirai T; Kim YH

  AACR Annual Meeting 2018., Apr. 2018, Peer-reviewed

  
• A clinical paired resistant model elucidated novel dual salvage signaling that confers alectinibresistance in ALK-rearranged lung cancer.

  Takahiro Tsuji; Hiroaki Ozasa; Wataru Aoki; Shunsuke Aburaya; Tomoko Funazo; Koh Furugaki; Yasushi Yoshimura; Hitomi Ajimizu; Ryoko Okutani; Yuto Yasuda; Takashi Nomizo; Kiyoshi Uemasu; Koichi Hasegawa; Hironori Yoshida; Yoshitaka Yagi; Hiroki Nagai; Yuichi Sakamori; Mitsuyoshi Ueda; Toyohiro Hirai; Young Hak Kim

  AACR annual meeting 2018, Apr. 2018, Peer-reviewed

  
• Efficacy of MCL1 inhibitor S63845 in small cell lung cancer.

  Yasuda Y; Ozasa H; Tsuji T; Nomizo T; Funazo T; Yoshida H; Sakamori Y; Hirai T; Kim YH

  AACR Annual Meeting 2018., Apr. 2018, Peer-reviewed

  
• 化学療法とオシメルチニブの併用が効果的であったEGFR変異陽性肺癌の一例

  大井昌寛; 吉田博徳; 阪森優一; 小笹裕晃; 平井豊博; 金永学

  第107回日本肺癌学会関西支部学術集会, Feb. 2018, Peer-reviewed

  
• Single nucleotide polymorphisms in PD-L1 and outcome in nivolumab-treated advanced non-small-cell lung cancer patients

  T. Nomizo; T. Funazo; H. Ozasa; T. Tsuji; Y. Yasuda; H. Yoshida; Y. Sakamori; H. Nagai; T. Hirai; Y. H. Kim

  ANNALS OF ONCOLOGY, Sep. 2017

  
• Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer.

  Tsuji T; Ozasa H; Sakamori Y; Nomizo T; Yagi Y; Nagai H; Kim YH; Mishima M

  AACR annual meeting 2017, Apr. 2017

  
• COPD合併非小細胞肺癌の予後

  味水 瞳; 小笹 裕晃; 佐藤 晋; 阪森 優一; 船造 智子; 安田 有斗; 野溝 岳

  第57回日本肺癌学会学術集会, Dec. 2016

  
• アレクチニブ耐性におけるABCB1/MDR1の役割と癌幹細胞性質

  辻 貴宏; 小笹 裕晃; 阪森 優一; 野溝 岳; 八木 由生; 永井 宏樹; 金 永学

  第57回日本肺癌学会学術集会, Dec. 2016

  
• HGF/c-METシグナル活性によるABCトランスポーターの発現上昇と抗癌剤耐性

  八木 由生; 小笹 裕晃; 國井 英治; 船造 智子; 安田 有斗; 野溝 岳; 辻 貴宏

  第57回日本肺癌学会学術集会, Dec. 2016

  
• 進行肺癌における抗癌剤効果予測因子としてのPDL1遺伝子多型の検討

  野溝 岳; 船造 智子; 小笹 裕晃; 安田 有斗; 辻 貴宏; 吉田 博徳; 八木 由生; 阪森 優一; 永井 宏樹; 金 永学

  第57回日本肺癌学会学術集会, Dec. 2016

  
• 当院でのニボルマブ投与例における有効性と安全性に関する検討

  船造 智子; 安田 有斗; 野溝 岳; 辻 貴宏; 吉田 博徳; 八木 由生; 阪森 優一; 永井 宏樹; 小笹 裕晃; 金 永学

  第57回日本肺癌学会学術集会, Dec. 2016

  
• 局所進行非小細胞肺癌に対する術前化学放射線治療後の組織学的治療効果の予測因子の検討

  光吉隆真; 松尾幸憲; 新谷尭; 飯塚裕介; 小笹裕晃; 永井宏樹; 金永学; 陳豊史; 園部誠; 伊達洋至; 中島直樹; 吉澤明彦

  日本肺癌学会総会号, Nov. 2016

  
• 京大病院におけるチーム医療の取り組みと安全性対策 免疫チェックポイント阻害剤を安全に使用するために

  永井 宏樹; 金 永学; 大塚 篤司; 寺尾 真琴; 池見 泰明; 黒田 貴子; 浜辺 陽子; 安田 有斗; 船造 智子; 野溝 岳; 辻 貴宏; 八木 由生; 吉田 博徳; 阪森 優一; 小笹 裕晃; 松本 繁巳; 武藤 学

  肺癌, Nov. 2016

  
• Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small cell lung cancer

  H. Ajimizu; H. Ozasa; S. Sato; Y. Sakamori; T. Funazo; Y. Yasuda; T. Nomizo; T. Tsuji; H. Yoshida; Y. Yagi; H. Nagai; A. Sato; M. Tsuchiya; S. Muro; Y. Nagasaka; M. Mishima; Y. H. Kim

  ANNALS OF ONCOLOGY, Oct. 2016

  
• Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small cell lung cancer

  H. Ajimizu; H. Ozasa; S. Sato; Y. Sakamori; T. Funazo; Y. Yasuda; T. Nomizo; T. Tsuji; H. Yoshida; Y. Yagi; H. Nagai; A. Sato; M. Tsuchiya; S. Muro; Y. Nagasaka; M. Mishima; Y.H. Kim

  ESMO 2016 Congress, Oct. 2016, Peer-reviewed

  
• Increased expression of ABCB1 could be associated with AZD9291 resistance in non-small cell lung cancer cell line PC9.

  Takashi Nomizo; Hiroaki Ozasa; Takahiro Tsuji; Yoshitaka Yagi; Hironori Yoshida; Yuuichi Sakamori; Hiroki Nagai; Yong Hak Kim

  第75回 日本癌学会学術集会 横浜, Oct. 2016

  
• Lung Cancer with COPD : From the View Point of the Oncologist

  小笹 裕晃; 佐藤 晋

  呼吸と循環, Aug. 2016

  
• Increased ALDH7A1 expression enhances the resistance to the anticancer drugs and colony formation in lung cancer cell lines

  Yuichi Sakamori; Hiroaki Ozasa; Eiji Kunii; Yoshitaka Yagi; Takahiro Tsuji; Takeshi Nomizo; Hiroki Nagai; Young Hak Kim; Ken Maeno; Tetsuya Oguri; Michiaki Mishima

  CANCER RESEARCH, Jul. 2016

  
• 当院におけるALK融合遺伝子転座陽性進行非小細胞肺癌の使用経験

  安田 有斗; 辻 貴宏; 船造 智子; 野溝 岳; 八木 由生; 吉田 博徳; 阪森 優一; 永井 宏樹; 小笹 裕晃; 金 永学

  第104回日本肺癌学会関西支部学術集会, Jul. 2016

  
• Nivolumabにより胃炎を来たしステロイドが奏功した一例

  門場 啓一郎; 永井 宏樹; 宮本 心一; 大塚 篤司片岡; 竜貴; 安田 有斗; 船造 智子; 辻 貴宏; 野溝 岳; 八木 由生; 吉田 博徳; 阪森 優一; 小笹 裕晃; 金 永学

  第104回日本肺癌学会関西支部学術集, Jul. 2016

  
• Overexpression of ABC transporters through HGF/c-MET activation results in anti-cancer drug resistance in SCLC

  Yoshitaka Yagi; Hiroaki Ozasa; Eiji Kunii; Takashi Nomizo; Takahiro Tsuji; Yuichi Sakamori; Young Hak Kim; Ken Maeno; Tetsuya Oguri; Michiaki Mishima

  107th Annual Meeting of American Association for Cancer Research New Orlines, Apr. 2016, Invited

  
• COPD合併肺癌の予後～COPD治療の意義～

  味水 瞳; 佐藤 晋; 小笹裕晃; 阪森優一; 永井宏樹; 佐藤 篤靖; 金 永学; 室 繫郎; 平井豊博; 三嶋理晃

  第56回日本呼吸器学会学術講演会 京都, Apr. 2016

  
• Increased ALDH7A1 expression enhances the resistance to the anticancer drugs and tumorigenesis in lung cancer cell lines

  Yuichi Sakamori; Hiroaki Ozasa; Eiji Kunii; Yoshitaka Yagi; Takahiro Tsuji; Takashi Nomizo; Hiroki Nagai; Young Hak Kim; Ken Maeno; Tetsuya Oguri; Michiaki Mishima

  107th Annual Meeting of American Association for Cancer Research (AACR) New Orleans, Apr. 2016

  
• Increased expression of ABCB1/MDR1 could be associated with alectinib resistance in ALK-rearranged lung cancer cells.

  Takahiro Tsuji; Hiroaki Ozasa; Yuichi Sakamori; Takashi Nomizo; Yoshitaka Yagi; Hiroki Nagai; Young Hak Kim; Michiaki Mishima

  107th Annual Meeting of American Association for Cancer Research (AACR) New Orleans, Apr. 2016

  
• 辻 貴宏, 阪森 優一, 小笹 裕晃, 八木 由生, 味水 瞳, 野溝 岳, 永井 宏樹,金 永学, 三嶋 理晃

  進行非小細胞肺癌における血清HGFと臨床的予後の検討

  第56回日本肺癌学会総会 横浜, Nov. 2015

  
• 脳転移患者におけるBevacizumab併用初回化学療法の後方視的検討

  八木 由生; 阪森 優一; 味水 瞳; 野溝 岳; 辻 貴宏; 永井 宏樹; 小笹 裕晃; 金 永学; 三嶋 理晃

  肺癌, Oct. 2015

  
• EGFR遺伝子変異陽性肺癌症例におけるerlotinib/bevacizumab併用療法の後方視的検討

  永井 宏樹; 金 永学; 味水 瞳; 野溝 岳; 辻 貴宏; 八木 由生; 吉田 博徳; 中奥 敬史; 阪森 優一; 小笹 裕晃; 三嶋 理晃

  肺癌, Oct. 2015

  
• 再発小細胞肺癌に対するnab-paclitaxelの有用性の検討

  吉田 博徳; 金 永学; 野溝 岳; 辻 貴宏; 中奥 敬史; 八木 由生; 阪森 優一; 永井 宏樹; 小笹 裕晃; 三嶋 理晃

  肺癌, Oct. 2015

  
• 進行非小細胞肺癌における血清HGFと臨床的予後の検討

  辻 貴宏; 阪森 優一; 小笹 裕晃; 八木 由生; 味水 瞳; 野溝 岳; 永井 宏樹; 金 永学; 三嶋 理晃

  肺癌, Oct. 2015

  
• ABCB1上昇がALK融合遺伝子陽性肺癌細胞におけるアレクチニブ耐性の原因となる

  辻 貴宏; 小笹 裕晃; 阪森 優一; 八木 由生; 味水 瞳; 野溝 岳; 永井 宏樹; 金 永学; 三島 理晃

  第74回日本癌学会学術集会 名古屋, Oct. 2015

  
• 小細胞肺癌におけるHGF/c-METシグナルの活性化によるABC トランスポーターの発現上昇と抗癌剤耐性

  八木 由生; 小笹 裕晃; 前野 健; 辻 貴宏; 阪森 優一; 味水 瞳; 野溝 岳; 永井 宏樹; 金 永学; 小栗 鉄也; 三嶋 理晃

  第74回日本癌学会学術集会 2015年10月9日 名古屋, Oct. 2015

  
• 肺癌細胞株におけるALDH７A1の発現と抗がん剤耐性および腫瘍形成能との関連性の検討

  阪森 優一; 小笹 裕晃; 國井 英治; 八木 由夫; 辻 貴宏; 味水 瞳; 野溝 岳; 永井 宏樹; 金 永学; 前野 健; 小栗 鉄也; 三嶋 理晃

  第74回日本癌学会学術集会 名古屋, Oct. 2015

  
• 小細胞肺癌により傍腫瘍性神経症候群を来し、抗Hu抗体、抗Yo抗体、抗CV-2抗体が陽性であった1例

  織谷 康之; 味水 瞳; 小笹 裕晃; 野溝 岳; 阪森 優一; 永井 宏樹; 金 永学; 三嶋 理晃

  肺癌, Aug. 2015

  
• Clinical significance of serum hepatocyte growth factor (sHGF) in patients with advanced non-small-cell lung cancer (NSCLC).

  Takahiro Tsuji; Yuichi Sakamori; Hiroaki Ozasa; Hitomi Ajimizu; Yoshitaka Yagi; Hiroki Nagai; Michiaki Mishima; Young Hak Kim

  JOURNAL OF CLINICAL ONCOLOGY, May 2015

  
• Crizotinib耐性ALK陽性肺癌の脳転移に対し、Alectinibが著効した1例

  味水 瞳; 金 永学; 小笹 裕晃; 永井 宏樹; 阪森 優一; 八木 由生; 吉田 博徳; 中奥 敬史; 三嶋 理晃

  肺癌, Feb. 2015

  
• 細胞障害性抗癌剤耐性化におけるc‐MET発現上昇の意義

  OZASA HIROAKI; MAENO KEN; OGURI TETSUYA; KUNII EIJI; YAGI YOSHIO; SAKAMORI YUICHI; KIN EIGAKU; MISHIMA MICHIAKI; NIIMI AKIO

  日本肺癌学会総会号, 05 Oct. 2014

  
• EGFR遺伝子変異陽性の未治療非小細胞肺癌に対する初回治療レジメンの意義についての検討

  SAKAMORI YUICHI; KIN EIGAKU; YAGI YOSHIO; YOSHIDA HIRONORI; NAKAOKU TAKASHI; NAGAI HIROKI; OZASA HIROAKI; MISHIMA MICHIAKI

  日本肺癌学会総会号, 05 Oct. 2014

  
• 当院における非小細胞肺癌に対するnab‐PTXの使用経験

  TSUJI TAKAHIRO; OZASA HIROAKI; KIN EIGAKU; MISUI HITOMI; YAGI YOSHIO; SAKAMORI YUICHI; NAGAI HIROKI; MISHIMA MICHIAKI

  日本肺癌学会総会号, 05 Oct. 2014

  
• PHASE II STUDY OF PEMETREXED plus ERLOTINIB IN PRETREATED Non-Sq-NSCLC Pts WITH wtEGFR (TALIMTA STUDY)

  Takashi Nishimura; Young Hak Kim; Hiroki Nagai; Hiroaki Ozasa; Yuichi Sakamori; Shigeaki Iwatsubo; Tomoko Nishimura; Hironobu Sunadome; Toshiyuki Iwata; Michiaki Mishima

  ANNALS OF ONCOLOGY, Oct. 2014

  
• OCT6はプラチナ製剤の細胞内取込と薬剤耐性に関与する(Organic cation transporter, OCT6 mediates uptake and resistance to platinum drugs)

  國井 英治; 小栗 鉄也; 前野 健; 笠井 大嗣; 小笹 裕晃; 上村 剛大; 高桑 修; 新実 彰男

  日本癌学会総会記事, Sep. 2014

  
• 術前導入化学放射線療法により放射線肺臓炎を発症した肺癌手術症例の検討

  横山 雄平; 山田 徹; 大政 貢; 陳 豊史; 佐藤 雅昭; 毛受 暁史; 青山 晃博; 佐藤 寿彦; 園部 誠; 板東 徹; 伊達 洋至; 松尾 幸憲; 久保 武; 小笹 裕晃

  肺癌, Apr. 2014

  
• 当院でのCrizotinib投与症例9例の検討

  小笹 裕晃; 八木 由生; 中奥 敬史; 吉田 博徳; 阪森 優一; 永井 宏樹; 金 永学; 三嶋 理晃; 伊達 洋至

  肺癌, Apr. 2014

  
• 当院におけるEGFR遺伝子変異陽性肺癌に対するerlotinib使用症例の臨床的検討

  島 寛; 金 永学; 阪森 優一; 中奥 敬史; 八木 由生; 吉田 博徳; 永井 宏樹; 小笹 裕晃; 三嶋 理晃

  肺癌, Apr. 2014

  
• TAS-115, a novel MET + VEGFRs dual inhibitor, decreases the cytotoxic anticancer drug resistance in lung canceｒ

  Eiji Kunii; Hiroaki Ozasa; Tetsuya Oguri; Ken Maeno; Osamu Takakuwa; akehiro Uemura; Niimi Akio

  American Association for Cancer Reserch 105th Annual Meeting, Apr. 2014

  
• EGFR遺伝子変異の無い進行再発Non‐Sq‐NSCLCに対するエルロチニブ+ペメトレキセド併用療法の第II相試験(TALIMTA STUDY)

  NISHIMURA TAKASHI; KIM YOUNG HAK; NAGAI HIROKI; OZASA HIROAKI; SAKAMORI YUICHI; IWATSUBO SHIGEAKI; NISHIMURA TOMOKO; SUNADOME HIRONOBU; IWATA TOSHIYUKI; MISHIMA MICHIAKI

  日本臨床腫瘍学会学術集会(CD-ROM), 2014

  
• CIRCULATING TUMOR CELLS AS A PROGNOSTIC MARKER IN METASTATIC NON-SMALL-CELL LUNG CANCER PATIENTS RECEIVING CHEMOTHERAPY

  Y. Sakamori; Y. Kim; H. Yoshioka; M. Hirabayashi; K. Onaru; M. Fukui; T. Hirata; H. Nagai; H. Ozasa; M. Mishima

  ANNALS OF ONCOLOGY, Nov. 2013

  
• 非小細胞癌に対するBevacizumab使用症例のretrospective解析

  OKUNO TAKEHIRO; KIN EIGAKU; NAKAOKU TAKASHI; YAGI YOSHIO; YOSHIDA HIRONORI; SAKAMORI YUICHI; NAGAI HIROKI; OZASA HIROAKI; MISHIMA MICHIAKI

  日本肺癌学会総会号, 05 Oct. 2013

  
• EGFR陽性肺癌に対するEGFR‐TKIの治療効果予測は臨床因子から可能か?

  YAGI YOSHIO; KANENAGA MANABU; SAKAMORI YUICHI; NAKAOKU TAKASHI; YOSHIDA HIRONORI; NAGAI HIROKI; OZASA HIROAKI; MISHIMA MICHIAKI

  日本肺癌学会総会号, 05 Oct. 2013

  
• 肺癌細胞におけるOrganic Cation Transporterとシスプラチン耐性

  KASAI HIROTSUGU; OGURI TETSUYA; OZASA HIROAKI; HIJIKATA TOSHIAKI; YOKOYAMA MIDORI; UEMURA TAKEHIRO; KUNII EIJI; TAKAKUWA OSAMU; OKUBO HITOSHI; MIYAZAKI MIKINORI; MAENO KEN; NAKAMURA ATSUSHI; NIIMI AKIO

  日本呼吸器学会誌, Mar. 2013

  
• 遠隔転移を有する非小細胞肺癌患者における循環血液中腫瘍細胞数測定の臨床的意義

  SAKAMORI YUICHI; KIM YOUNGHAK; YOSHIOKA HIROSHIGE; HIRABAYASHI MASATAKA; ONARU KOICHI; FUKUI MOTONARI; HIRATA TOSHIKI; NAGAI HIROKI; OZASA HIROAKI; MISHIMA MICHIAKI

  日本臨床腫瘍学会学術集会(CD-ROM), 2013

  
• 外側胸動脈肺静脈瘻の1例

  FUJITA HARUNA; OKUBO HITOSHI; HIJIKATA TOSHIAKI; UEMURA TAKEHIRO; KUNII EIJI; OZASA HIROAKI; TAKAKUWA OSAMU; MIYAZAKI MIKINORI; MAENO KEN; OGURI TETSUYA; NAKAMURA ATSUSHI; SATO SHIGEKI; NIIMI AKIO

  結核, Nov. 2012

  
• 肺癌症例における1日1回型フェンタニルクエン酸塩貼付剤の有効性の検討

  TAKAKUWA OSAMU; OGURI TETSUYA; HISAKATA HISATOSHI; UEMURA TAKEHIRO; KUNII EIJI; KASAI HIROTSUGU; OZASA HIROAKI; OKUBO HITOSHI; MIYAZAKI MIKINORI; MAENO KEN; NAKAMURA ATSUSHI; SATO SHIGEKI; NIIMI AKIO

  肺癌, Oct. 2012

  
• 気管支鏡下に気管支内腔の真菌塊を観察できた慢性壊死性肺アスペルギルス症の1例

  TAKAKUWA OSAMU; MIYAZAKI MIKINORI; HIJIKATA TOSHISATO; UEMURA TAKEHIRO; OZASA HIROAKI; OKUBO HITOSHI; MAENO KEN; OGURI TETSUYA; NAKAMURA ATSUSHI; SATO SHIGEKI; NIIMI AKIO

  気管支学, Sep. 2012

  
• チミジレートシンターゼコピー数は、肺癌におけるペメトレキセド感受性の予測因子となり得るか(Thymidylate synthase copy number as a predictive biomarker for pemetrexed sensitivity in lung cancer)

  笠井 大嗣; 小栗 鉄也; 小笹 裕晃; 上村 剛大; 國井 英治; 高桑 修; 宮崎 幹規; 前野 健; 佐藤 滋樹; 新実 彰男

  日本癌学会総会記事, Aug. 2012

  
• 局所麻酔下胸腔鏡にて診断したIgG4関連胸膜炎の1例

  MIYAZAKI MIKINORI; UEMURA TAKEHIRO; KUNII EIJI; OZASA HIROAKI; OKUBO HITOSHI; MAENO KEN; OGURI TETSUYA; NAKAMURA ATSUSHI; SATO SHIGEKI

  気管支学, May 2012

  
• Significance of thymidylate synthase copy numbers for resistance to pemetrexed in lung cancer

  Daishi Kasai; Tetsuya Oguri; Hiroaki Ozasa; Takehiro Uemura; Eiji Kunii; Osamu Takakuwa; Hirotsugu Ohkubo; Mikinori Miyazaki; Ken Maeno; Shigeki Sato

  CANCER RESEARCH, Apr. 2012

  
• A SNP538(G > A) in ABCC11/MRP8 determines sensitivity for antimetabolites

  Takehiro Uemura; Tetsuya Oguri; Hiroaki Ozasa; Daishi Kasai; Eiji Kunii; Osamu Takakuwa; Hirotsugu Ohkubo; Mikinori Miyazaki; Ken Maeno; Shigeki Sato

  CANCER RESEARCH, Apr. 2012

  
• 既治療非小細胞肺癌に対するS-1単剤化学療法の検討

  浅野 貴光; 冨田 勇樹; 新美 岳; 小栗 鉄也; 高桑 修; 中尾 心人; 國井 英治; 上村 剛大; 小笹 裕晃; 大久保 仁嗣; 宮崎 幹規; 前野 健; 中村 敦; 佐藤 滋樹

  肺癌, Apr. 2012

  
• 小細胞肺癌におけるc‐MET活性と抗癌剤耐性の基礎的検討

  KUNII EIJI; OGURI TETSUYA; OZASA HIROAKI; UEMURA TAKEHIRO; OKUBO HITOSHI; MIYAZAKI MIKINORI; MAENO KEN; NAKAMURA ATSUSHI; SATO SHIGEKI

  日本呼吸器学会誌, Mar. 2012

  
• 気管分岐部に腫瘤を呈した再発悪性リンパ腫の1例

  OKUBO HITOSHI; UEMURA TAKEHIRO; KUNII EIJI; OZASA HIROAKI; MIYAZAKI MIKINORI; MAENO KEN; OGURI TETSUYA; NAKAMURA ATSUSHI; SATO SHIGEKI

  気管支学, Jan. 2012

  
• Pemetrexed治療効果予測因子としてのTS遺伝子増幅の有用性についての基礎的検討

  KASAI HIROTSUGU; OGURI TETSUYA; OZASA HIROAKI; UEMURA TAKEHIRO; TAKAKUWA OSAMU; KUNII EIJI; OKUBO HITOSHI; MIYAZAKI MIKINORI; MAENO KEN; NAKAMURA ATSUSHI; SATO SHIGEKI

  肺癌, Oct. 2011

  
• アムルビシン感受性予測因子としてのNAD(P)H:quinone oxidoreductase 1(NQO1)遺伝子多型の検討(C609T polymorphism of NAD(P)H:quinone oxidoreductase 1 as a predictive biomarker for response to amrubicin)

  高桑 修; 小栗 鉄也; 小笹 裕晃; 上村 剛大; 國井 英治; 笠井 大嗣; 宮崎 幹規; 前野 健; 佐藤 滋樹

  日本癌学会総会記事, Sep. 2011

  
• ABCC11/MRP8のSNPP538(G>A)はDPD阻害フッ化ピリミジンの感受性を規定する(A SNP538(G>A) in ABCC11/MRP8 determine sensitivity for DPD inhibitory fluoropyrimidines)

  上村 剛大; 小栗 鉄也; 小笹 裕晃; 高桑 修; 笠井 大嗣; 宮崎 幹規; 前野 健; 佐藤 滋樹

  日本癌学会総会記事, Sep. 2011

  
• 肺扁平上皮癌に合併した気管支平滑筋腫の1例

  MIYAZAKI MIKINORI; UEMURA TAKEHIRO; KUNII EIJI; OZASA HIROAKI; OKUBO HITOSHI; MAENO KEN; OGURI TETSUYA; NAKAMURA ATSUSHI; SATO SHIGEKI

  気管支学, Sep. 2011

  
• 当院における局所麻酔下胸腔鏡症例の検討―胸水検査所見と胸腔鏡下生検結果の対比から―

  MIYAZAKI MIKINORI; TOMITA YUKI; OZASA HIROAKI; KASAI HIROTSUGU; KUNII EIJI; IWASHIMA YASUJI; SUZUKI TAKESHI; MAENO KEN; OGURI TETSUYA; NAKAMURA ATSUSHI; SATO SHIGEKI

  気管支学, 20 May 2011

  
• 肺癌細胞株におけるamrubicinolの殺細胞効果とNAD(P)H:quinine oxidoreductase1発現

  TAKAKUWA OSAMU; OGURI TETSUYA; OZASA HIROAKI; UEMURA TAKEHIRO; KASAI HIROTSUGU; KUNII EIJI; SUZUKI TAKESHI; IWASHIMA YASUJI; MIYAZAKI MIKINORI; MAENO KEN; NAKAMURA ATSUSHI; SATO SHIGEKI

  日本呼吸器学会雑誌, 10 Mar. 2011

  
• 局所麻酔下胸腔鏡を行った卵巣癌による癌性胸膜炎の2例

  HARADA KANAKO; MIYAZAKI MIKINORI; KUNII EIJI; KASAI HIROTSUGU; OZASA HIROAKI; IWASHIMA YASUJI; SUZUKI TAKESHI; MAENO KEN; OGURI TETSUYA; NAKAMURA ATSUSHI; SATO SHIGEKI

  肺癌, 20 Feb. 2011

  
• 真菌感染を認めた気管支カルチノイドの1例

  MORIYAMA SATORU; YOKOTA KEISUKE; HIKOSAKA YU; SASAKI HIDEFUMI; YANO TOMONORI; FUJII YOSHITAKA; KUNII EIJI; KASAI HIROTSUGU; OZASA HIROAKI; IWASHIMA YASUJI; SUZUKI TAKESHI; MIYAZAKI MIKINORI; MAENO KEN; OGURI TETSUYA; NAKAMURA ATSUSHI; SATO SHIGEKI; NISHIO MASAYUKI

  気管支学, Jan. 2011

  
• 胸水細胞診においてセルブロック法により診断が確定した胸膜中皮腫の3例

  OZASA HIROAKI; MAENO KEN; MIYAZAKI MIKINORI; KUNII EIJI; OGURI TETSUYA; KASAI HIROTSUGU; SUZUKI TAKESHI; IWASHIMA YASUJI; NAKAMURA ATSUSHI; SATO SHIGEKI

  肺癌, 20 Dec. 2010

  
• THE IMPORTANT FACTOR OF ANTIFOLATE RESISTANCE

  Takehiro Uemura; Tetsuya Oguri; Hiroaki Ozasa; Tatsuya Yoshida; Makoto Nakao; Daishi Kasai; Osamu Takakuwa; Takeshi Suzuki; Mikinori Miyazaki; Hirokazu Komatsu; Shigeki Sato; Ryuzo Ueda

  ANNALS OF ONCOLOGY, Nov. 2010

  
• 高齢者肺癌に対するアムルビシンの安全性と有用性に関する検討

  KUNII EIJI; UEMURA TAKEHIRO; KASAI HIROTSUGU; OZASA HIROAKI; TAKAKUWA OSAMU; SUZUKI TAKESHI; MIYAZAKI MIKINORI; MAENO KEN; OGURI TETSUYA; NAKAMURA ATSUSHI; SATO SHIGEKI

  肺癌, 05 Oct. 2010

  
• 肺癌におけるMDR1遺伝子多型とアムルビシン効果予測

  TAKAKUWA OSAMU; OGURI TETSUYA; OZASA HIROAKI; UEMURA TAKEHIRO; KUNII EIJI; KASAI HIROTSUGU; SUZUKI TAKESHI; MIYAZAKI MIKINORI; MAENO KEN; NAKAMURA ATSUSHI; SATO SHIGEKI

  肺癌, 05 Oct. 2010

  
• 局所麻酔下胸腔鏡を施行した膵性胸水の1例

  MIYAZAKI MIKINORI; KUNII EIJI; KASAI HIROTSUGU; OZASA HIROAKI; SUZUKI TAKESHI; IWASHIMA YASUJI; MAENO KEN; OGURI TETSUYA; SATO SHIGEKI; NAKAMURA ATSUSHI

  気管支学, 25 Sep. 2010

  
• Increased MET expression in anticancer drug resistant cells

  Hiroaki Ozasa; Tetsuya Oguri; Takehiro Uemura; Osamu Takakuwa; Makoto Nakao; Mikinori Miyazaki; Ken Maeno; Shigeki Sato; Ryuzo Ueda

  「がん」若手研究者ワークショップ, Sep. 2010

  
• ABCC11/MRP8の一塩基変異多型とpemetrexed感受性(A SNP of ABCC11/MRP8 determines sensitivity for pemetrexed)

  上村 剛大; 小栗 鉄也; 小笹 裕晃; 高桑 修; 笠井 大嗣; 宮崎 幹規; 前野 健; 佐藤 滋樹

  日本癌学会総会記事, Aug. 2010

  
• 抗癌剤耐性化におけるヘパラナーゼの活性上昇(Enhanced heparanase activity in anticancer drug resistant cells)

  笠井 大嗣; 小栗 鉄也; 小笹 裕晃; 前野 健; 上村 剛大; 高桑 修; 宮崎 幹規; 佐藤 滋樹

  日本癌学会総会記事, Aug. 2010

  
• 非小細胞肺癌細胞株における抗癌剤耐性化とヘパラナーゼ発現

  TAKAKUWA OSAMU; OGURI TETSUYA; OZASA HIROAKI; MAENO KEN; UEMURA TAKEHIRO; NAKAO MAKOTO; TOMITA YUKI; KASAI HIROTSUGU; SUZUKI TAKESHI; MIYAZAKI MIKINORI; NAKAMURA ATSUSHI; SATO SHIGEKI; UEDA RYUZO

  日本呼吸器学会雑誌, 20 Mar. 2010

  
• 葉酸代謝拮抗薬の耐性規定因子

  UEMURA TAKEHIRO; OGURI TETSUYA; OZASA HIROAKI; YOSHIDA TATSUYA; NAKAO MAKOTO; KASAI DAISHI; TAKAKUWA OSAMU; SUZUKI TAKESHI; MIYAZAKI MIKINORI; KOMATSU HIROKAZU; SATO SHIGEKI; UEDA RYUZO

  日本臨床腫瘍学会学術集会プログラム・抄録集, 2010

  
• Heparanase overexpression and resistance to anticancer agents

  Hiroaki Ozasa; Tetsuya Oguri; Takehiro Uemura; Osamu Takakuwa; Makoto Nakao; Mikinori Miyazaki; Ken Maeno; Shigeki Sato; Ryuzo Ueda

  The 19th International Symposium of Hiroshima Cancer Seminar in conjunction with Three Universities' Consortium, Nov. 2009

  
• 肺癌細胞株におけるAmrubicin耐性規定因子の検討

  TAKAKUWA OSAMU; OGURI TETSUYA; OZASA HIROAKI; UEMURA TAKEHIRO; TOMITA YUKI; SUZUKI TAKESHI; MIYAZAKI MIKINORI; MAENO KEN; SATO SHIGEKI; UEDA RYUZO

  肺癌, 05 Oct. 2009

  
• 非小細胞肺癌細胞株におけるABCトランスポーターとvinorelbine耐性との関連(ATP-binding cassette transporter family and vinorelbine in non-small cell lung cancer cells)

  高桑 修; 小栗 鉄也; 小笹 裕晃; 中尾 心人; 上村 剛大; 宮崎 幹規; 前野 健; 佐藤 滋樹; 上田 龍三

  日本癌学会総会記事, Aug. 2009

  
• 当院におけるサルコイドーシス診断についての検討

  OTA CHIHARU; MIYAZAKI MIKINORI; NAKAO SHINTO; UEMURA TAKEHIRO; OZASA HIROAKI; TAKAKUWA OSAMU; IWASHIMA YASUJI; MAENO KEN; KUTSUNA TAKEO; OGURI TETSUYA; NAKAMURA ATSUSHI; SATO SHIGEKI

  日本呼吸器学会雑誌, 10 May 2009

  
• Increased expression of MRP8/ABCC11 in antifolate drug-resistant lung cancer cells

  Takehiro Uemura; Hiroaki Ozasa; Tetsuya Oguri; Osamu Takakuwa; Mikinori Miyazaki; Ken Maeno; Shigeki Sato; Ryuzo Ueda

  CANCER RESEARCH, May 2009

  
• ABCC10/MRP7 is associated with vinorelbine resistance in non-small-cell lung cancer

  Osamu Takakuwa; Takehiro Uemura; Hiroaki Ozasa; Tetsuya Oguri; Mikinori Miyazaki; Ken Maeno; Shigeki Sato; Ryuzo Ueda

  CANCER RESEARCH, May 2009

  
• Significance of heparanase overexpression in anticancer agent resistant lung cancer cell lines

  Hiroaki Ozasa; Tetsuya Oguri; Takehiro Uemura; Osamu Takakuwa; Makoto Nakao; Mikinori Miyazaki; Ken Maeno; Shigeki Sato; Ryuzo Ueda

  American associated for cancer research 100th Annual Meeting, Apr. 2009

  
• 気管支内腫瘤性病変にて再発した腹膜原発漿液性乳頭腺癌の1例

  NAKAO SHINTO; OGURI TETSUYA; MAENO KEN; UEMURA TAKEHIRO; OZASA HIROAKI; OTA CHIHARU; TAKAKUWA OSAMU; IWASHIMA YASUHITO; MIYAZAKI MIKINORI; KUTSUNA TAKEO; NAKAMURA ATSUSHI; SATO SHIGEKI

  気管支学, 25 Mar. 2009

  
• 非小細胞肺癌患者におけるhuman equilibrative nucleoside transporter 1の発現と予後についての検討

  NAKAO MAKOTO; OGURI TETSUYA; TAKAKUWA OSAMU; UEMURA TAKEHIRO; OZASA HIROAKI; MIYAZAKI MIKINORI; SATO SHIGEKI; UEDA RYUZO

  日本臨床腫瘍学会学術集会プログラム・抄録集, 2009

  
• 肺MALTリンパ腫の化学療法後に発症した肺小細胞癌の1例

  NAKAO SHINTO; KATO MUNEHIRO; MAENO TAKESHI; OGURI TETSUYA; UEMURA TAKEHIRO; OZASA HIROAKI; OTA CHIHARU; TAKAKUWA OSAMU; IWAJIMA YASUHITO; KUSUMOTO SHIGERU; MIYAZAKI MIKINORI; KUTSUNA TAKEO; NAKAMURA ATSUSHI; SATO SHIGEKI; UEDA RYUZO; INAGAKI HIROSHI

  肺癌, 20 Dec. 2008

  
• 抗癌剤耐性化におけるヘパラナーゼ発現の意義についての検討

  OZASA HIROAKI; OGURI TETSUYA; MAENO KEN; UEMURA TAKEHIRO; OTA CHIHARU; MIYAZAKI MIKINORI; NAKAMURA ATSUSHI; SATO SHIGEKI; UEDA RYUZO

  肺癌, 05 Oct. 2008

  
• Alteration of cytotoxity to gemcitabine in pemetrexed-resistant lung cancer cell lines

  Hiroaki Ozasa; Tetsuya Oguri; Takehiro Uemura; Osamu Takakuwa; Makoto Nakao; Mikinori Miyazaki; Ken Maeno; Shigeki Sato; Ryuzo Ueda

  日本癌学会第67回総会, Oct. 2008

  
• 肺癌細胞株における薬剤排出ポンプMRP8/ABCC11とpemetrexed耐性(MRP8/ABCC11 confers resistance to pemetrexed in lung cancer cell lines)

  上村 剛大; 小栗 鉄也; 小笹 裕晃; 中尾 心人; 高桑 修; 宮崎 幹規; 佐藤 滋樹; 上田 龍三

  日本癌学会総会記事, Sep. 2008

  
• Establishment of pemetrexed-resistant lung cancer cell lines and the mechanism of resistance

  Hiroaki Ozasa; Tetsuya Oguri; Takehiro Uemura; Yuji Bessho; Mikinori Miyazaki; Ken Maeno; Hiroyoshi Maeda; Shigeki Sato; Ryuzo Ueda

  American Association for Cancer Reserch 99th Annual Meeting, Apr. 2008

  
• 薬剤排出ポンプMRP7/ABCC10と薬剤耐性

  UEMURA TAKEHIRO; OGURI TETSUYA; OZASA HIROAKI; BESSHO YUJI; MIYAZAKI MIKINORI; MAEDA HIROYOSHI; SATO SHIGEKI; YANO HIROKI; KOMATSU HIROKAZU; UEDA RYUZO

  日本臨床腫瘍学会学術集会プログラム・抄録集, 2008

  
• 肺癌細胞株におけるPemetrexed耐性規定因子の検討

  OZASA HIROAKI; OGURI TETSUYA; BESSHO YUJI; UEMURA TAKEHIRO; MIYAZAKI MIKINORI; MAENO KEN; MAEDA HIROYOSHI; NAKAMURA ATSUSHI; SATO SHIGEKI; UEDA RYUZO

  肺癌, 15 Oct. 2007

  
• 薬剤排出ポンプMRP7/ABCC10遺伝子発現とpaclitaxel耐性

  UEMURA TAKEHIRO; OGURI TETSUYA; OZASA HIROAKI; BESSHO YUJI; MIYAZAKI MIKINORI; MAENO KEN; MAEDA HIROYOSHI; NAKAMURA ATSUSHI; SATO SHIGEKI; UEDA RYUZO

  肺癌, 15 Oct. 2007

  
• 経過中腹腔内リンパ節転移により肝外性閉塞性黄疸を来たした肺癌の2例

  OZASA HIROAKI; OGURI TETSUYA; TAKANO YUKO; IWASHIMA YASUJI; BESSHO YUJI; MIYAZAKI MIKINORI; KATO MUNEHIRO; MORITA HIROKI; MAENO KEN; MAEDA HIROYOSHI; NAKAMURA ATSUSHI; SATO SHIGEKI; UEDA RYUZO

  肺癌, 20 Apr. 2007

  
• サルコイドーシス患者単球の遺伝子発現―Propionibacterium acnesに対する反応として―

  MAEDA HIROYOSHI; SATO SHIGEKI; NIIMI TAKASHI; NAKAMURA ATSUSHI; OGURI TETSUYA; MAENO KEN; KUTSUNA TAKEO; KATO MUNEHIRO; MORITA HIROKI; MIYAZAKI MIKINORI; BESSHO YUJI; IWASHIMA YASUJI; TAKANO YUKO; OZASA HIROAKI; UEDA RYUZO

  日本呼吸器学会雑誌, 10 Apr. 2007

  
• Thymidylate synthase is a predictive marker for pemetrexed sensitivity in non-small cell lung cancer

  Hiroaki Ozasa; Tetsuya Oguri; Yuji Bessho; Mikinori Miyazaki; Ken Maeno; Hiroyoshi Maeda; Shigeki Sato; Ryuzo Ueda

  American Association for Cancer Reserch 98th Annual Meeting, Apr. 2007

  
• 気管支鏡所見を追跡し診断に至った肺MALTリンパ腫の1例

  MIYAZAKI MIKINORI; OZASA HIROAKI; TAKANO HIROKO; IWASHIMA YASUHITO; BESSHO YUJI; KATO MUNEHIRO; MORITA HIRONORI; MAENO TAKESHI; OGURI TETSUYA; MAEDA HIROYOSHI; NAKAMURA ATSUSHI; SATO SHIGEKI; UEDA RYUZO

  気管支学, 25 Jan. 2007

  
• 多発性骨髄腫に合併した肺腺癌の1例

  OZASA HIROAKI; TOKUYAMA KIYONOBU; OGURI TETSUYA; TAKANO YUKO; BESSHO YUJI; MIYAZAKI MIKINORI; MAENO KEN; MAEDA HIROYOSHI; SATO SHIGEKI; UEDA RYUZO

  肺癌, 20 Dec. 2006

  
• 肺癌細胞株におけるpemetrexed耐性規定因子としてのthymidylate synthaseの検討

  OZASA HIROAKI; OGURI TETSUYA; BESSHO YUJI; TAKANO YUKO; MIYAZAKI MIKINORI; MAENO KEN; MAEDA HIROYOSHI; SATO SHIGEKI; UEDA RYUZO

  肺癌, 05 Nov. 2006

  
• 縦隔に再発した髄外性形質細胞腫の1例

  NISHIMAKI ANA; BESSHO YUJI; OZASA HIROAKI; TAKANO HIROKO; MIYAZAKI MOTONORI; MAENO TAKESHI; OGURI TETSUYA; MAEDA HIROYOSHI; SATO SHIGEKI; UEDA RYUZO

  気管支学, 25 Sep. 2006

  
• 帝王切開後に子かん様のけいれん発作で発症したくも膜下出血の一例

  KOZASA HIROAKI; YAMADA KENTARO; TAKADA KOJI; HATTORI MANABU; OKITA KENJI; MORISHITA MANABU; MAKI MINA; MATSUKAWA NORIYUKI; YAMAWAKI TAKEMORI

  臨床神経学, 01 Feb. 2004

  
• 癌性リンパ管症で発症し,経気管支鏡下肺生検により確定診断につながった1症例

  OZASA HIROAKI; MURAMATSU HIDEKI; SUGIHARA KANJI; ISHII AKIKO; ITO REI; TANAKA SATORU; BESSHO YUJI; HATTORI NORIKO; ACHIWA HIROYUKI

  気管支学, 25 Jan. 2004

  

Presentations

• ALK陽性肺癌の最適な治療

  小笹裕晃

  ALK-positive mNSCLC Seminar., 15 Oct. 2024, Invited

  
• 胸部悪性腫瘍におけるCGP検査の実施意義

  小笹裕晃

  肺がんゲノム医療フォーラム in新潟, 24 Sep. 2024

  
• ALK陽性肺癌に対する最適な治療方針を考える

  Pfizer Lung Cancer Web Symposium, 02 Jul. 2024, Invited

  
• 臨床試験の解釈から考える肺がん治療 ～高齢者の治療戦略も含めて～

  Lung Cancer Seminar in OSAKA, 07 Jun. 2024, Invited

  
• 非小細胞肺癌の薬物療法について ~肺癌の実臨床におけるCQにどう向き合うか~

  令和6年度 第1回 若手医師のための臨床に役立つ呼吸器セミナー, 18 May 2024

  
• 肺がんにおけるCGP検査の実施意義

  小笹裕晃

  The Tokyo Cooperative Oncology Group Conference, 16 Apr. 2024, Invited

  
• 最適なICI治療選択は？ ～KEYNOTE-189, 407を振り返る～

  小笹裕晃

  肺癌 Skill Up Seminar in 名古屋, 11 Apr. 2024, Invited

  
• 肺がんにおける適切なICI治療選択は？ ～最新知見からKEYNOTE-189、407を振り返る～

  小笹裕晃

  Lung Cancer Clinical Seminar in TOKAI, 22 Feb. 2024, Invited

  
• 肺がんにおける適切なICI治療選択は？ ～最新知見からKEYNOTE-189、407を振り返る～

  小笹裕晃

  Lung Cancer Clinical Seminar 2024 ~肺癌診療の実態に迫る～ 京都, 30 Jan. 2024, Invited

  
• 胸部悪性腫瘍におけるCGP検査の実施意義

  小笹裕晃

  Tochigi expert Genome Seminar on Lung Cancer 栃木, 25 Jan. 2024, Invited

  
• ALK・ROS1融合遺伝子肺癌の最適な治療方針を考える ～肺癌におけるゲノムプロファイリングの必要性を踏まえて～

  小笹裕晃

  第102回日本呼吸器学会近畿地方会・第7回日本呼吸器ケア・リハビリテーション学会近畿支部学術集会合同学会 ランチョンセミナー４, 20 Jan. 2024, Invited

  
• 肺がんにおける免疫チェックポイント阻害薬の位置づけ

  小笹裕晃

  膠原病 irAE を考える会 in 京都, 09 Nov. 2023, Invited

  
• 胸部悪性腫瘍におけるCGP検査の実施意義

  小笹裕晃

  若手医師のための肺癌勉強会 in 神戸, 21 Dec. 2023, Invited

  
• マルチ遺伝子検査と希少肺がんにおける薬物療法 ～BRAF,MET 阻害薬を中心に～

  小笹裕晃

  Lung Cancer Hands on Seminar in Kyoto, 28 Oct. 2023, Invited

  
• ALK陽性肺癌の１次治療におけるロルラチニブの果たすべき役割とは？

  小笹裕晃

  Lung Cancer Internet Symposium, 05 Oct. 2023, Invited

  
• 肺がんにおける適切なICI治療選択は？～最新知見からKEYNOTE-189,407を振り返る～

  小笹裕晃

  Lung Cancer Clinical Seminar 2023~肺癌診療の実際に迫る~, 29 Sep. 2023, Invited

  
• ALK陽性肺癌の１次治療におけるロルラチニブの 果たすべき役割とは？ ～最新のフォローアップデータを交えて～

  小笹裕晃

  第118回日本肺癌学会関西支部学術集会 学術セミナー, 17 Jun. 2023, Invited

  
• 胸部悪性腫瘍におけるCGP検査の実施意義

  桜山肺がんゲノム適正使用・連携を考える会, 26 May 2023, Invited

  
• 肺癌におけるCGP検査の活用を考える！

  CGP Expert Board Web Seminar -On Lung Cancer-, 15 May 2023, Invited

  
• 肺癌転移性脳腫瘍の生体内観察モデルを用いた 新規治療薬の検討

  第63回日本呼吸器学会学術講演会、日本呼吸器財団研究助成成果報告, 29 Apr. 2023, Invited

  
• ALK陽性肺癌の治療戦略を考える ～基礎から臨床まで～

  小笹裕晃

  Lung Cancer Seminar, 10 Feb. 2023, Invited

  
• 希少肺癌の診断と治療 ～実臨床におけるALK陽性肺癌を中心に ～

  小笹裕晃

  京滋希少肺癌講演会2022, 22 Mar. 2022, Invited

  
• 「ALK陽性肺癌の最適治 療を考える ～アレクチ ニブの位置づけ～」

  小笹裕晃

  第98回日本呼吸器学会近畿地方会、ランチョンセミナー, 11 Dec. 2021, Invited

  
• 当院におけるマルチコンパニオン診断を用いた最適化治療について ~実臨床の経験を中心に~

  小笹裕晃

  Lung Cancer Precision Medicine Web Seminar, 26 Aug. 2021, Invited

  
• 「当院におけるNGSマルチCDx用の検体採取について」

  小笹裕晃

  第113回日本肺癌学会関西支部学術集会ランチョンセミナー, 27 Feb. 2021, Invited

  
• COPD合併肺癌の予後

  小笹 裕晃

  第89回 閉塞性肺疾患研究会ミニシンポジウム, 18 Jul. 2015, Invited

  

Books and Other Publications

• 最新 呼吸器内科・外科学

  小笹裕晃, Joint work, 総論：腫瘍マーカー、喀痰検査 各論：進行肺癌の治療（細胞障害性抗がん剤、分子標的治療）

  株式会社 メディカルレビュー, 30 Oct. 2019

  
• 中山書店 内科学書 改訂第９版

  辻貴宏、小笹裕晃, Joint work, 悪性腫瘍の薬物治療・放射線治療

  中山書店, Aug. 2019

  
• 呼吸と循環

  小笹 裕晃; 佐藤 晋, Contributor, 肺癌診療専門内科医からみたCOPD

  医学書院, Aug. 2016, Not refereed

  

External funds: Kakenhi

• Development of new therapeutic strategies for driver mutation-positive lung cancer

  Grant-in-Aid for Scientific Research (C)

  Basic Section 53030:Respiratory medicine-related

  Kyoto University

  Hiroaki Ozasa

  From 01 Apr. 2019, To 31 Mar. 2022, Project Closed

  肺癌;YAP1;治療初期生存;ドライバー遺伝子;分子標的治療薬;抗癌剤耐性;患者由来癌細胞;プロテオーム解析

  https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-19K08601/
• Application of iPS cell technology to lung regeneration and development of bioresource for elucidating the mechanisms of lung diseases

  Grant-in-Aid for Scientific Research (A)

  Kyoto University

  Mishima Michiaki

  From 01 Apr. 2015, To 31 Mar. 2018, Project Closed

  分子細胞呼吸学;iPS細胞;肺臓器再生;疾患モデリング;分子細胞呼吸器学

  https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-15H02537/
• Clinical and therapeutic implications of nestin in small cell lung cancer

  Grant-in-Aid for Scientific Research (C)

  Nagoya City University

  Ken Maeno

  From 01 Apr. 2014, To 31 Mar. 2018, Project Closed

  小細胞肺癌;ネスチン;肺癌;分子標的

  https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-26461193/
• 肺癌転移性肝腫瘍における肝転移生体内観察モデルを用いた新規治療戦略の開発

  Grant-in-Aid for Scientific Research (C)

  Basic Section 53030:Respiratory medicine-related

  Kyoto University

  吉田 博徳

  From 01 Apr. 2023, To 31 Mar. 2026, Granted

  肺癌;転移性肝腫瘍;生体内観察モデル

  https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23K07599/
• Exploration of Novel Biomarkers for Immune Checkpoint Inhibitors Using Single Nucleotide Polymorphisms

  Grant-in-Aid for Scientific Research (C)

  Basic Section 50020:Tumor diagnostics and therapeutics-related

  Kyoto University

  野溝 岳

  From 01 Apr. 2024, To 31 Mar. 2027, Granted

  バイオマーカー;免疫チェックポイント阻害薬;肺癌;抗がん剤;薬物療法

  https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-24K10403/

External funds: others

• 脳内微小環境と癌細胞の相互作用を解明する異分野融合的解析法

  次世代がん医療加速化研究事業

  From Apr. 2021, To Mar. 2023

  辻貴宏

  荒川芳輝　小笹裕晃
• 肺癌転移性脳腫瘍の生体内観察モデルを用いた、新規治療薬の検討

  日本呼吸器財団

  From 01 Nov. 2020, To 31 Mar. 2023

  小笹裕晃

Education

Teaching subject(s)

• From 01 Apr. 2022, To 31 Mar. 2023

  Advanced Cancer Nursing Lecture I

  M298, Spring, Graduate School of Medicine, 2
• From Apr. 2013, To Mar. 2014

  Clinical Overview of Internal Medicine III

  Spring, 医学部（人間健康科学科）
• From Apr. 2013, To Mar. 2014

  Neurology & Neurosurgery

  Spring, 医学部（人間健康科学科）
• From Apr. 2013, To Mar. 2014

  Geriatric Medicine

  Spring, 医学部（人間健康科学科）
• From Apr. 2014, To Mar. 2015

  Clinical Overview of Internal Medicine III

  Spring, 医学部（人間健康科学科）
• From Apr. 2014, To Mar. 2015

  Neurology & Neurosurgery

  Spring, 医学部（人間健康科学科）
• From Apr. 2014, To Mar. 2015

  Geriatric Medicine

  Spring, 医学部（人間健康科学科）
• From Apr. 2015, To Mar. 2016

  Clinical Overview of Internal Medicine I

  Spring, 医学部（人間健康科学科）
• From Apr. 2016, To Mar. 2017

  Clinical Overview of Internal Medicine I

  Spring, 医学部（人間健康科学科）
• From Apr. 2017, To Mar. 2018

  Clinical Overview of Internal Medicine I

  Spring, 医学部（人間健康科学科）
• From Apr. 2019, To Mar. 2020

  Pathophysiology

  Spring, 医学研究科（人間健康科学系専攻）
• From Apr. 2020, To Mar. 2021

  Advanced Cancer Nursing Lecture I

  Spring, 医学研究科（人間健康科学系専攻）
• From Apr. 2021, To Mar. 2022

  Advanced Cancer Nursing Lecture I

  Spring, 医学研究科（人間健康科学系専攻）

Student achievements: Awards

• 第81回日本癌学会学術総会　JCA若手研究者ポスター賞

  山添正敏, Oct. 2022
• 若手奨励賞

  辻　貴宏, 日本肺癌学会, 12 Nov. 2020

Academic, Social Contribution

Committee Memberships

• From Jan. 2024, To Present

  倫理委員会, 日本肺癌学会
• From Apr. 2022, To Present

  地域連携部会, 京都府がん医療戦略推進会議
• From Dec. 2016, To Present

  評議員, 日本肺癌学会

Social Contribution

• 肺癌市民公開講座

  Host, Planner

  京都市、明治安田、中外製薬, From 17 Nov. 2024